



Public Health
England

Data tables of the Unlinked Anonymous Monitoring Survey of HIV and Hepatitis in People Who Inject Drugs

Surveillance Update: July 2017

Survey conducted by:

National Infections Service, Public Health England

Survey is supported by:

Public Health Wales and Public Health Agency Northern Ireland

Further Information:

Information on the Unlinked Anonymous Monitoring Surveys can be found at:

<https://www.gov.uk/government/statistics/people-who-inject-drugs->

About these data tables

These tables present data from the Unlinked Anonymous Monitoring Survey of People Who Inject Drugs (PWID) in contact with specialist services. This annual cross-sectional survey is co-ordinated by Public Health England, with support from Public Health Wales and Public Health Agency Northern Ireland. It is targeted at those who inject psychoactive drugs. These data tables are updated annually and made available on the Public Health England website. Data from the biennial sub-survey of people who inject image and performance enhancing drugs can be found in a separate set of tables published on the same web-page. A commentary on the surveillance tables is published in the Health Protection Report (HPR) which is also available on the Public Health England web pages.

Data are presented for the whole of England, Wales and Northern Ireland, and sub-divided by country and English region. Two regional breakdowns of England have been used in this dataset: the Public Health England Regions and the standard statistical regions (as defined in nomenclature of territorial units for statistics [NUTS]). In some of these areas, data from several years have been combined when less than 100 samples have been collected in a year. Regional level data should be interpreted *cautiously* as the survey recruits participants through a nationally reflective sample of the services provided to people who inject drugs. For clarity, percentages are given to two significant figures, and confidence intervals are not presented.

This set of data tables presents data for the period 2006 to 2016. Data from the survey for earlier years (the survey has been running since 1990) can be found in past sets of data tables which are available via the Public Health England website.

Suggested citation

For citation purposes the following is suggested: Public Health England, National Infection Service. Unlinked Anonymous Monitoring Survey of People Who Inject Drugs: data tables. July 2017. London, Public Health England.

Summary of survey methodology

This voluntary unlinked anonymous survey recruits people who inject drugs through specialist agencies throughout England, Wales and Northern Ireland. These agencies provide a range of services to those who inject illicit drugs, from medical treatment to needle and syringe programmes and outreach work. People using these services that are either currently injecting drugs or who have done so previously are asked to take part in the survey by service staff. Those who agree to take part provide a biological specimen that is tested anonymously for HIV, hepatitis C and hepatitis B. Behavioural and limited demographic information is collected through a brief anonymous subject-completed questionnaire linked to the specimen but unlinked from any client identifying information. This includes questions on the uptake of diagnostic (voluntary confidential) testing for HIV and hepatitis C, hepatitis B vaccination and the sharing of injecting equipment; participants may opt out of answering all questions. The questions asked have varied over time, and are focused on the use of psychoactive drugs.

The biological sample collected in the survey was changed from an oral fluid to a dried blood spot (DBS) during 2009 and 2010. From 2011 onwards, only DBS samples have been collected. The sensitivities of the tests on a DBS sample for antibodies to HIV, hepatitis C and hepatitis B core antigen, and that on an oral fluid sample for antibodies to HIV, are all close to 100%. However, the sensitivity of the oral fluid sample test for antibodies to hepatitis C is about 92% and that for antibodies to the hepatitis B core antigen is about 75%.

Number of sites recruiting participants each year: 2006-2016

Area	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
London	13	10	11	12	9	10	14	13	14	12	10
Elsewhere in England and Wales	46	47	52	46	49	47	48	50	48	46	47
Northern Ireland	4	3	3	2	4	4	4	4	4	4	4
Total	63	60	66	60	62	61	66	67	66	62	61

Content

- Table 1: HIV prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016
- Table 2: Hepatitis B prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016
- Table 3: Hepatitis C prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016
- Table 4: Level of direct sharing among current injectors by gender and age; England, Wales and Northern Ireland: 2006-2016
- Table 5: Level of direct & indirect sharing among current injectors by gender and age; England, Wales and Northern Ireland: 2006-2016
- Table 6: Self-reported hepatitis B vaccine uptake among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016
- Table 7: Uptake of voluntary confidential testing (VCT) for HIV among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016
- Table 8: Uptake of voluntary confidential testing (VCT) for hepatitis C virus (HCV) among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016
- Table 9: Symptoms of an injection site infection among those who injected during the preceding year by gender and age; England, Wales and Northern Ireland: 2006-2015
- Table 10: Sexual intercourse (anal or vaginal), number of sexual partners, and condom use during the preceding year; England, Wales and Northern Ireland: 2006-2016
- Table 11: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; England: 2006-2016
- Table 12: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE Region North: 2006-2016
- Table 13: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE Region Midlands & East: 2006-2016
- Table 14: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE Region South: 2006-2016
- Table 15: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE & NUTS Region London: 2006-2016
- Table 16: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region East of England: 2006-2016
- Table 17: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region South East: 2006-2016
- Table 18: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region South West: 2006-2016
- Table 19: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region West Midlands: 2006-2016
- Table 20: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region North West: 2006-2016
- Table 21: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region Yorkshire & Humber: 2006-2016
- Table 22: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region East Midlands: 2006-2016
- Table 23: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region North East: 2006-2016
- Table 24: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; Wales: 2006-2016
- Table 25: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; Northern Ireland: 2006-2016
- Table 26: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use in those who began injecting in the last three years: 2006-2016
- Table 27: Characteristics of the people who inject drugs recruited across England, Wales and Northern Ireland: 2006-2016

Abbreviations and footnotes used in this set of data tables

List of abbreviations used in this data set:

Anti-HIV	= antibodies to HIV
Anti-HBc	= antibodies to hepatitis B core antigen, a marker of current or past hepatitis B infection
HBsAg	= hepatitis B surface antigen, a marker of current hepatitis B infection
Anti-HCV	= antibodies to hepatitis C virus
HCV	= hepatitis C virus
VCT	= voluntary confidential testing
DBS	= dried blood spot
NUTS	= nomenclature of territorial units for statistics

List of footnotes used in this data set:

~ Age and gender not provided by all participants.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

§ The sensitivity of the oral fluid test for anti-HBc is approximately 75%.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

†† The sensitivity of the oral fluid test for antibodies to hepatitis C (anti-HCV) is approximately 92%.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

†††† HBsAg Prevalence = (number of samples tested HBsAg positive / number of samples tested anti-HBc positive)x100.

‡ Sharing of needles and syringes among those who had last injected during the four weeks preceding participation in the survey.

‡‡ Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

* Prescribed a detox or maintenance drug regime.

** Self-reports of ever receiving money, goods or drugs in exchange for sex.

*** Regional breakdowns not provided due to small numbers.

Table 1: HIV prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016

		<i>Year</i>	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
All	Anti-HIV Prevalence †		1.3%	1.1%	1.6%	1.5%	1.1%	1.2%	1.3%	1.1%	1.0%	1.0%	0.85%
	Number of samples anti-HIV positive		42	41	51	49	35	35	43	34	31	26	24
	Total number of samples collected		3,240	3,580	3,209	3,289	3,288	2,838	3,389	3,144	3,091	2,721	2,812
Gender ~	Male	Anti-HIV Prevalence †	1.4%	1.2%	1.7%	1.5%	1.1%	1.4%	1.3%	1.2%	1.2%	1.0%	0.85%
		Number of samples anti-HIV positive	32	32	40	35	27	29	32	28	28	20	17
		Total number of samples collected	2,332	2,603	2,344	2,378	2,433	2,102	2,485	2,291	2,241	1,978	1,991
	Female	Anti-HIV Prevalence †	1.0%	0.88%	1.3%	1.4%	0.76%	0.88%	1.2%	0.73%	0.36%	0.84%	0.88%
		Number of samples anti-HIV positive	9	8	11	12	6	6	10	6	3	6	7
		Total number of samples collected	870	908	826	851	790	683	851	817	826	718	793
Age ~	Under 25	Anti-HIV Prevalence †	0.44%	0.59%	1.0%	0.25%	0.59%	0.84%	0.70%	0.54%	0.57%	1.7%	0%
		Number of samples anti-HIV positive	2	3	4	1	2	2	2	1	1	2	0
		Total number of samples collected	455	509	409	400	341	239	287	185	175	116	71
	25 to 34	Anti-HIV Prevalence †	1.3%	0.77%	1.5%	1.1%	0.58%	1.1%	0.84%	0.72%	0.41%	0.90%	0.92%
		Number of samples anti-HIV positive	18	12	19	14	7	11	10	8	4	7	7
		Total number of samples collected	1,412	1,567	1,296	1,246	1,214	1,027	1,186	1,107	964	782	765
	35 and over	Anti-HIV Prevalence †	1.6%	1.7%	2.0%	2.1%	1.5%	1.4%	1.6%	1.3%	1.3%	1.0%	0.83%
		Number of samples anti-HIV positive	20	23	27	31	24	20	29	23	24	17	16
		Total number of samples collected	1,278	1,373	1,361	1,474	1,598	1,465	1,781	1,801	1,898	1,780	1,922

~ Age and gender not provided by all participants.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

Table 2: Hepatitis B prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016

Notes:

Anti-HBc is a marker for current or past hepatitis B infection. In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HBc tests on these two sample types are different[§]. HBsAg is a marker for current infection.

Year		2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016	
Sample type		Oral fluid [§]	Oral fluid [§]	Oral fluid [§]	Oral fluid [§]	DBS	Oral fluid [§]	DBS	DBS	DBS	DBS	DBS	DBS	DBS	
All	Anti-HBc Prevalence ^{††}	28%	20%	18%	17%		16%		16%	17%	16%	14%	13%	14%	
	Proportion anti-HBc positive	21%	15%	13%	13%	11%	14%	15%	16%	17%	16%	14%	13%	14%	
	Number of samples anti-HBc positive	677	546	425	371	59	150	338	442	561	518	445	357	395	
	Total number of samples collected	3,240	3,580	3,207	2,753	536	1,077	2,211	2,838	3,389	3,144	3,091	2,721	2,793	
Gender [~]	Male	Anti-HBc Prevalence ^{††}	28%	20%	18%	17%		17%		16%	18%	17%	15%	14%	15%
		Proportion anti-HBc positive	21%	15%	14%	14%	10%	13%	16%	16%	18%	17%	15%	14%	15%
		Number of samples anti-HBc positive	486	389	322	280	40	110	265	344	441	382	344	272	295
	Total number of samples collected	2,332	2,603	2,342	1,982	396	817	1,616	2,102	2,485	2,291	2,241	1,978	1,981	
	Female	Anti-HBc Prevalence ^{††}	27%	21%	16%	15%		15%		14%	13%	16%	12%	11%	12%
		Proportion anti-HBc positive	20%	16%	12%	12%	14%	16%	12%	14%	13%	16%	12%	11%	12%
Number of samples anti-HBc positive		177	146	99	84	19	38	65	93	108	130	100	82	97	
Total number of samples collected	870	908	826	714	137	233	557	683	851	817	826	718	784		
Age [~]	Under 25	Anti-HBc Prevalence ^{††}	11%	7.9%	4.2%	4.3%		8.3%		5.4%	4.9%	4.3%	2.3%	1.7%	2.8%
		Proportion anti-HBc positive	8.4%	5.9%	3.2%	4.0%	1.0%	7.5%	7.2%	5.4%	4.9%	4.3%	2.3%	1.7%	2.8%
		Number of samples anti-HBc positive	38	30	13	12	1	10	15	13	14	8	4	2	2
	Total number of samples collected	455	509	409	299	101	134	207	239	287	185	175	116	71	
	25 to 34	Anti-HBc Prevalence ^{††}	20%	14%	11%	10%		8.5%		9.0%	9.3%	10%	5.7%	4.5%	5.5%
		Proportion anti-HBc positive	15%	10%	7.9%	8.0%	7.1%	5.9%	8.7%	9.0%	9.3%	10%	5.7%	4.5%	5.5%
		Number of samples anti-HBc positive	208	160	103	82	16	23	72	92	110	113	55	35	42
	Total number of samples collected	1,412	1,567	1,296	1,020	226	387	827	1,027	1,186	1,107	964	782	762	
	35 and over	Anti-HBc Prevalence ^{††}	42%	32%	28%	26%		24%		22%	23%	22%	20%	17%	18%
Proportion anti-HBc positive		32%	24%	21%	20%	20%	22%	22%	22%	23%	22%	20%	17%	18%	
Number of samples anti-HBc positive		405	329	282	253	39	111	242	328	410	390	377	310	341	
Total number of samples collected	1,278	1,373	1,359	1,282	192	495	1,103	1,465	1,781	1,801	1,898	1,780	1,907		
Among those anti-HBc positive	HBsAg Prevalence ^{†††}								4.8%	5.7%	3.5%	4.0%	3.1%	3.0%	
	Number of samples HBsAg positive								21	32	18	18	11	12	
Total number of samples collected									433	561	518	445	350	395	

[§] The sensitivity of the oral fluid test for anti-HBc is approximately 75%.

[~] Age and gender not provided by all participants.

^{††} Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

^{†††} HBsAg Prevalence = (number of samples tested HBsAg positive / number of samples tested anti-HBc positive)x100.

Table 3: Hepatitis C prevalence in people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016

Notes:

In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV tests on these two sample types are different[¶].

Year		2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016	
Sample type		Oral fluid [¶]	Oral fluid [¶]	Oral fluid [¶]	Oral fluid [¶]	DBS	Oral fluid [¶]	DBS	DBS	DBS	DBS	DBS	DBS	DBS	
All	Anti-HCV Prevalence^{†††}	44%	43%	43%	47%		47%		43%	47%	49%	49%	50%	53%	
	Proportion anti-HCV positive	41%	39%	40%	43%	47%	41%	48%	43%	47%	49%	49%	50%	53%	
	Number of samples anti-HCV positive	1,316	1,412	1,274	1,183	252	442	1,051	1,234	1,601	1,543	1,517	1,371	1,462	
	Total number of samples collected	3,240	3,580	3,209	2,753	536	1,077	2,211	2,838	3,389	3,144	3,091	2,721	2,774	
Gender[~]	Male	Anti-HCV Prevalence^{†††}	45%	43%	43%	47%		48%		45%	48%	48%	50%	50%	53%
		Proportion of samples anti-HCV positive	41%	40%	40%	43%	45%	41%	49%	45%	48%	48%	50%	50%	53%
		Number of samples anti-HCV positive	959	1,036	938	859	180	337	797	941	1,199	1,109	1,115	996	1,038
	Total number of samples collected	2,332	2,603	2,344	1,982	396	817	1,616	2,102	2,485	2,291	2,241	1,978	1,968	
	Female	Anti-HCV Prevalence^{†††}	42%	41%	41%	47%		42%		40%	45%	51%	47%	51%	52%
		Proportion of samples anti-HCV positive	39%	37%	38%	42%	52%	40%	41%	40%	45%	51%	47%	51%	52%
Number of samples anti-HCV positive		336	340	313	301	71	93	231	275	383	415	388	364	407	
Total number of samples collected	870	908	826	714	137	233	557	683	851	817	826	718	778		
Age[~]	Under 25	Anti-HCV Prevalence^{†††}	25%	21%	22%	26%		27%		22%	24%	28%	25%	28%	25%
		Proportion of samples anti-HCV positive	23%	20%	20%	21%	37%	25%	26%	22%	24%	28%	25%	28%	25%
		Number of samples anti-HCV positive	106	100	83	62	37	34	54	52	68	52	43	32	18
	Total number of samples collected	455	509	409	299	101	134	207	239	287	185	175	116	71	
	25 to 34	Anti-HCV Prevalence^{†††}	36%	35%	36%	38%		36%		36%	38%	42%	40%	40%	44%
		Proportion of samples anti-HCV positive	33%	32%	33%	35%	41%	31%	37%	36%	38%	42%	40%	40%	44%
		Number of samples anti-HCV positive	472	507	426	355	92	119	309	366	446	467	385	316	332
	Total number of samples collected	1,412	1,567	1,296	1,020	226	387	827	1,027	1,186	1,107	964	782	755	
	35 and over	Anti-HCV Prevalence^{†††}	59%	59%	56%	59%		58%		53%	57%	55%	56%	56%	57%
Proportion anti-HCV positive		55%	54%	51%	54%	59%	54%	58%	53%	57%	55%	56%	56%	57%	
Number of samples anti-HCV positive		697	744	699	691	113	265	642	773	1,015	998	1,060	1,001	1,077	
Total number of samples collected	1,278	1,373	1,361	1,282	192	495	1,103	1,465	1,781	1,801	1,898	1,780	1,895		

[¶] The sensitivity of the oral fluid test for antibodies to hepatitis C (anti-HCV) is approximately 92%.

[~] Age and gender not provided by all participants.

^{†††} Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

Table 4: Level of direct sharing among current injectors[‡] by gender and age; England, Wales and Northern Ireland: 2006-2016

		<i>Year</i>	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
All	Level of direct sharing[‡]	23%	23%	19%	19%	21%	17%	14%	16%	17%	16%	17%	
	Number reporting direct sharing	445	487	343	339	363	224	236	265	259	227	241	
	Total number answering question	1,910	2,093	1,798	1,814	1,701	1,305	1,660	1,622	1,540	1,406	1,430	
Gender[~]	Male	Level of direct sharing[‡]	22%	22%	18%	17%	20%	16%	13%	15%	15%	14%	15%
		Number reporting direct sharing	315	351	235	234	254	160	167	188	181	146	157
	Total number answering question	1,432	1,586	1,328	1,382	1,299	1,020	1,261	1,219	1,169	1,056	1,063	
	Female	Level of direct sharing[‡]	27%	27%	23%	24%	27%	22%	17%	19%	21%	23%	23%
Number reporting direct sharing		126	130	105	102	101	62	67	75	78	79	83	
Total number answering question	465	486	452	418	380	280	393	397	370	346	365		
Age[~]	Under 25	Level of direct sharing[‡]	29%	26%	22%	27%	30%	24%	23%	31%	20%	25%	20%
		Number reporting direct sharing	100	100	60	71	64	33	41	38	24	16	10
	Total number answering question	345	384	272	264	215	137	181	121	118	65	49	
	25 to 34	Level of direct sharing[‡]	23%	25%	20%	20%	22%	17%	14%	17%	18%	21%	22%
		Number reporting direct sharing	202	247	159	147	150	89	93	111	100	99	95
	Total number answering question	863	984	802	751	691	523	643	646	557	466	440	
35 and over	Level of direct sharing[‡]	19%	18%	17%	14%	18%	16%	12%	13%	15%	13%	14%	
	Number reporting direct sharing	126	125	110	105	136	96	92	111	130	111	131	
Total number answering question	657	680	662	731	742	613	795	841	849	867	929		

[~] Age and gender not provided by all participants.

[‡] Sharing of needles and syringes among those who had last injected during the four weeks preceding participation in the survey.

Table 5: Level of direct & indirect sharing among current injectors^{††} by gender and age; England, Wales and Northern Ireland: 2006-2016

		<i>Year</i>	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
All	Level of sharing (direct & indirect) ^{††}	46%	45%	40%	36%	39%	35%	34%	39%	38%	38%	39%	
	Number reporting sharing	888	964	700	656	663	460	566	641	597	542	571	
	Total number answering question	1,914	2,135	1,765	1,815	1,705	1,300	1,657	1,636	1,558	1,414	1,447	
Gender [~]	Male	Level of sharing (direct & indirect) ^{††}	45%	44%	38%	34%	37%	34%	32%	38%	36%	36%	37%
		Number reporting sharing	646	712	495	466	477	347	402	472	425	386	398
		Total number answering question	1,437	1,627	1,302	1,384	1,300	1,015	1,256	1,230	1,183	1,063	1,075
	Female	Level of sharing (direct & indirect) ^{††}	51%	50%	44%	44%	45%	40%	41%	42%	46%	44%	46%
		Number reporting sharing	235	243	198	185	174	111	160	166	171	154	172
		Total number answering question	464	488	445	417	383	281	395	399	373	347	370
Age [~]	Under 25	Level of sharing (direct & indirect) ^{††}	49%	45%	40%	45%	49%	46%	45%	54%	51%	43%	43%
		Number reporting sharing	166	175	106	120	106	63	81	65	60	28	21
		Total number answering question	342	391	267	264	215	137	181	121	118	65	49
	25 to 34	Level of sharing (direct & indirect) ^{††}	48%	46%	41%	37%	38%	35%	34%	39%	38%	41%	44%
		Number reporting sharing	414	459	317	283	266	182	217	255	215	194	197
		Total number answering question	869	1,003	780	755	694	522	641	652	561	469	443
	35 and over	Level of sharing (direct & indirect) ^{††}	43%	45%	39%	31%	37%	34%	32%	37%	37%	37%	37%
		Number reporting sharing	285	310	255	226	271	205	250	313	315	319	346
		Total number answering question	658	695	653	730	742	610	793	848	862	872	943

[~] Age and gender not provided by all participants.

^{††} Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 6: Self-reported hepatitis B vaccine uptake among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016

		<i>Year</i>	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
All	Hepatitis B vaccine uptake	65%	66%	72%	73%	74%	76%	75%	72%	72%	75%	72%	
	Number reporting hepatitis B vaccine	2,061	2,299	2,259	2,352	2,383	2,094	2,463	2,163	2,126	1,952	1,921	
	Total number answering question	3,180	3,491	3,140	3,204	3,199	2,748	3,287	3,011	2,936	2,595	2,682	
Gender ~	Male	Hepatitis B vaccine uptake	65%	66%	72%	73%	75%	76%	75%	72%	72%	75%	72%
		Number reporting hepatitis B vaccine	1,491	1,701	1,650	1,715	1,783	1,574	1,836	1,588	1,542	1,419	1,373
		Total number answering question	2,290	2,565	2,298	2,344	2,381	2,061	2,440	2,207	2,136	1,895	1,910
	Female	Hepatitis B vaccine uptake	64%	64%	72%	74%	74%	76%	74%	72%	73%	76%	71%
		Number reporting hepatitis B vaccine	556	574	587	611	577	513	619	566	577	529	545
		Total number answering question	864	892	814	831	782	675	834	784	792	694	765
Age ~	Under 25	Hepatitis B vaccine uptake	65%	61%	69%	73%	66%	76%	70%	66%	67%	68%	54%
		Number reporting hepatitis B vaccine	294	305	272	292	223	179	196	117	112	75	36
		Total number answering question	450	500	396	399	338	235	282	178	168	111	67
	25 to 34	Hepatitis B vaccine uptake	69%	69%	77%	77%	79%	79%	78%	75%	75%	76%	70%
		Number reporting hepatitis B vaccine	966	1,060	975	939	946	802	916	799	690	577	519
		Total number answering question	1,395	1,544	1,270	1,226	1,191	1,011	1,174	1,067	922	762	743
	35 and over	Hepatitis B vaccine uptake	60%	64%	69%	71%	73%	74%	74%	71%	72%	76%	73%
		Number reporting hepatitis B vaccine	750	874	925	1,025	1,140	1,070	1,288	1,228	1,305	1,286	1,351
		Total number answering question	1,254	1,357	1,345	1,447	1,568	1,438	1,740	1,733	1,813	1,702	1,842

~ Age and gender not provided by all participants.

Table 7: Uptake of voluntary confidential testing (VCT) for HIV among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016

		<i>Year</i>	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	
All	HIV VCT uptake	69%	68%	72%	75%	75%	77%	79%	76%	77%	79%	77%		
	Number reporting a VCT for HIV	2,137	2,318	2,224	2,344	2,358	2,047	2,473	2,269	2,234	2,028	2,092		
		Total number answering question	3,116	3,410	3,087	3,126	3,129	2,643	3,145	2,986	2,915	2,572	2,703	
Gender ~	Male	HIV VCT uptake	68%	67%	71%	74%	75%	77%	78%	75%	76%	78%	76%	
		Number reporting a VCT for HIV	1,517	1,661	1,605	1,684	1,743	1,521	1,815	1,647	1,612	1,469	1,465	
			Total number answering question	2,239	2,494	2,261	2,284	2,333	1,977	2,334	2,187	2,131	1,886	1,929
	Female	HIV VCT uptake	71%	72%	75%	79%	78%	79%	81%	78%	79%	81%	81%	
Number reporting a VCT for HIV		604	631	599	640	590	517	648	607	616	555	622		
		Total number answering question	847	876	797	814	761	655	797	779	776	681	767	
Age ~	Under 25	HIV VCT uptake	57%	57%	64%	72%	65%	65%	67%	64%	63%	65%	74%	
		Number reporting a VCT for HIV	251	280	248	272	209	145	183	112	102	74	50	
			Total number answering question	442	490	388	379	323	223	273	176	162	114	68
	25 to 34	HIV VCT uptake	68%	66%	71%	73%	73%	75%	79%	75%	74%	78%	73%	
		Number reporting a VCT for HIV	925	1,004	893	878	862	732	880	798	678	583	538	
			Total number answering question	1,366	1,520	1,265	1,204	1,176	973	1,117	1,059	913	750	739
35 and over	HIV VCT uptake	74%	74%	75%	77%	80%	81%	80%	78%	79%	80%	79%		
	Number reporting a VCT for HIV	914	970	989	1,095	1,220	1,121	1,338	1,338	1,431	1,356	1,484		
		Total number answering question	1,230	1,311	1,315	1,413	1,530	1,388	1,667	1,722	1,806	1,688	1,867	
Among those anti-HIV positive	Proportion aware of HIV infection	64%	64%	64%	63%	89%	88%	95%	96%	85%	84%	95%		
	Number aware of their HIV infection	25	21	28	27	25	28	37	27	22	21	21		
	Total number answering question	39	33	44	43	28	32	39	28	26	25	22		

~ Age and gender not provided by all participants.

Table 8: Uptake of voluntary confidential testing (VCT) for hepatitis C virus (HCV) among people who inject drugs by gender and age; England, Wales and Northern Ireland: 2006-2016

		<i>Year</i>	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
All	HCV VCT Uptake		75%	74%	77%	81%	82%	83%	83%	82%	83%	86%	84%
	Number reporting a VCT for HCV Total number answering question		2,296 3,071	2,493 3,359	2,371 3,062	2,524 3,100	2,530 3,093	2,117 2,543	2,510 3,014	2,483 3,011	2,470 2,968	2,245 2,616	2,280 2,709
Gender	Male	HCV VCT Uptake	74%	73%	76%	80%	82%	83%	83%	82%	84%	86%	83%
		Number reporting a VCT for HCV Total number answering question	1,642 2,221	1,804 2,463	1,712 2,241	1,824 2,267	1,887 2,307	1,580 1,901	1,848 2,236	1,809 2,207	1,807 2,161	1,644 1,914	1,614 1,937
	Female	HCV VCT Uptake	77%	77%	80%	84%	81%	84%	85%	84%	82%	85%	86%
		Number reporting a VCT for HCV Total number answering question	633 822	663 859	636 793	681 808	611 750	527 630	652 765	661 784	655 798	594 695	662 767
Age	Under 25	HCV VCT Uptake	66%	65%	68%	76%	71%	75%	70%	71%	68%	73%	76%
		Number reporting a VCT for HCV Total number answering question	283 429	312 482	261 382	285 377	225 318	162 216	183 261	125 177	116 170	82 113	52 68
	25 to 34	HCV VCT Uptake	75%	73%	76%	80%	80%	82%	84%	82%	82%	83%	79%
		Number reporting a VCT for HCV Total number answering question	1,018 1,349	1,091 1,492	951 1,246	955 1,194	925 1,158	773 948	905 1,083	872 1,067	763 935	627 758	584 736
	35 and over	HCV VCT Uptake	78%	79%	80%	84%	86%	86%	85%	84%	86%	88%	86%
		Number reporting a VCT for HCV Total number answering question	945 1,217	1,028 1,302	1,053 1,311	1,182 1,401	1,306 1,525	1,130 1,320	1,352 1,593	1,460 1,735	1,569 1,827	1,517 1,722	1,619 1,873
Among those anti-HCV positive		Proportion aware of HCV infection	55%	52%	50%	51%	55%	51%	54%	47%	52%	52%	52%
		Number aware of their HCV infection Total number answering question	639 1,165	641 1,241	555 1,112	631 1,242	711 1,303	530 1,035	703 1,308	629 1,344	678 1,297	619 1,184	663 1,271

~ Age and gender not provided by all participants.

Table 9: Symptoms^{SS} of an injection site infection among those who injected during the preceding year by gender and age; England, Wales and Northern Ireland: 2006-2016

		<i>Year</i>	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
All	Symptom^{SS} of injection site infection	35%	38%	34%	35%	35%	28%	29%	28%	31%	33%	36%	
	Number reporting symptom ^{SS}	655	787	629	636	528	448	588	536	565	547	602	
	Total number answering question	1,882	2,084	1,870	1,806	1,524	1,600	1,998	1,913	1,820	1,675	1,681	
Gender ~	Male	Symptom^{SS} of injection site infection	33%	36%	32%	33%	32%	26%	29%	26%	29%	31%	34%
		Number reporting symptom ^{SS}	464	563	451	446	373	319	430	371	389	382	421
		Total number answering question	1,403	1,563	1,398	1,353	1,179	1,237	1,503	1,430	1,340	1,245	1,232
	Female	Symptom^{SS} of injection site infection	40%	43%	38%	42%	45%	36%	32%	35%	37%	38%	40%
		Number reporting symptom ^{SS}	187	216	173	186	150	128	157	165	175	164	179
		Total number answering question	466	501	454	441	330	360	489	473	476	427	446
Age ~	Under 25	Symptom^{SS} of injection site infection	27%	35%	28%	34%	34%	26%	28%	20%	24%	39%	43%
		Number reporting symptom ^{SS}	82	115	75	80	67	42	59	28	31	34	23
		Total number answering question	308	329	271	236	196	162	208	141	129	88	53
	25 to 34	Symptom^{SS} of injection site infection	34%	36%	30%	34%	32%	25%	25%	26%	29%	30%	32%
		Number reporting symptom ^{SS}	287	354	239	252	188	159	192	191	190	163	170
		Total number answering question	835	980	805	744	590	635	768	739	653	548	535
	35 and over	Symptom^{SS} of injection site infection	38%	42%	40%	36%	37%	31%	33%	31%	33%	33%	38%
		Number reporting symptom ^{SS}	265	309	293	276	261	236	317	313	341	345	406
		Total number answering question	696	742	728	758	705	768	963	1,018	1,022	1,032	1,080

~ Age and gender not provided by all participants.

^{SS} Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

Table 10: Sexual intercourse (anal or vaginal), number of sexual partners, and condom use during the preceding year; England, Wales and Northern Ireland: 2006-2016

		<i>Year</i>	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
All	Proportion having sex (anal or vaginal) in preceding year		74%	74%	75%	74%	75%	73%	73%	70%	68%	66%	64%
	Number having sex in preceding year		2,359	2,536	2,326	2,318	2,323	1,997	2,377	2,120	2,001	1,731	1,716
	Total number answering question		3,167	3,430	3,107	3,145	3,116	2,738	3,254	3,034	2,945	2,604	2,693
Among those who had (anal or vaginal) sex in the preceding year													
All	Proportion with two or more partners		43%	42%	42%	41%	44%	46%	44%	41%	40%	40%	37%
	Number with two or more partners		980	1,023	944	897	961	875	1,021	838	768	676	607
	Total number answering question		2,267	2,436	2,250	2,205	2,209	1,921	2,312	2,026	1,917	1,677	1,634
Among those with two or more (anal or vaginal) sexual partners in preceding year													
All	Proportion always using a condom		19%	18%	22%	20%	22%	19%	17%	18%	22%	22%	23%
	Number always using a condom		169	181	194	168	196	150	153	128	143	124	114
	Total number answering question		912	979	889	844	878	777	924	705	657	576	508
Gender ~	Male	Proportion always using a condom	18%	17%	21%	17%	22%	19%	15%	18%	22%	20%	23%
		Number always using a condom	130	131	145	108	157	118	111	101	117	87	89
		Total number answering question	714	776	688	648	698	632	723	563	529	438	391
	Female	Proportion always using a condom	20%	23%	25%	31%	21%	22%	21%	19%	21%	27%	21%
		Number always using a condom	38	43	48	59	36	32	42	26	26	37	25
		Total number answering question	192	191	189	191	169	143	196	138	126	137	117
Age ~	Under 25	Proportion always using a condom	18%	14%	19%	17%	18%	14%	13%	7.4%	12%	17%	17%
		Number always using a condom	34	24	28	28	26	14	16	6	7	7	5
		Total number answering question	190	176	144	167	147	102	122	81	60	42	29
	25 to 34	Proportion always using a condom	19%	18%	17%	18%	22%	17%	14%	16%	17%	19%	19%
		Number always using a condom	84	91	76	66	84	58	57	49	46	40	36
		Total number answering question	454	507	436	368	381	340	413	304	264	214	194
	35 and over	Proportion always using a condom	19%	21%	28%	23%	26%	23%	21%	23%	27%	24%	26%
		Number always using a condom	47	57	78	68	84	72	77	72	89	77	72
		Total number answering question	248	277	275	290	327	319	368	315	326	316	281

~ Age and gender not provided by all participants.

Table 11: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; England: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	1.3%	1.2%	1.5%	1.6%		1.2%		1.3%	1.4%	1.2%	1.0%	1.0%	0.9%
Number of samples anti-HIV positive	39	37	44	46		35		32	43	32	27	23	21
Total number of samples collected	2,893	3,085	2,893	2,962		2,899		2,485	2,982	2,782	2,667	2,307	2,469
Anti-HBc Prevalence ††	29%	22%	19%	18%		17%		16%	18%	17%	15%	14%	15%
Proportion of samples anti-HBc positive	22%	16%	14%	15%	11%	16%	16%	16%	18%	17%	15%	14%	15%
Number of samples anti-HBc positive	634	506	402	355	59	142	317	404	528	481	404	319	359
Total number of samples collected	2,893	3,085	2,892	2,426	536	881	2,018	2,485	2,982	2,782	2,667	2,307	2,451
Anti-HCV Prevalence †††	46%	46%	44%	49%		49%		45%	49%	50%	50%	52%	54%
Proportion of samples anti-HCV positive	43%	42%	41%	45%	47%	45%	49%	45%	49%	50%	50%	52%	54%
Number of samples anti-HCV positive	1,233	1,292	1,177	1,092	252	395	991	1,115	1,466	1,398	1,345	1,191	1,321
Total number of samples collected	2,893	3,085	2,893	2,426	536	881	2,018	2,485	2,982	2,782	2,667	2,307	2,432
Hepatitis B vaccine uptake	65%	66%	72%	73%		75%		77%	75%	71%	72%	75%	71%
Number reporting hepatitis B vaccine uptake	1,838	1,982	2,039	2,117		2,120		1,844	2,169	1,903	1,815	1,644	1,682
Total number answering question	2,839	3,008	2,828	2,893		2,816		2,408	2,886	2,662	2,532	2,198	2,353
HCV VCT uptake	75%	75%	77%	81%		83%		83%	83%	82%	83%	86%	84%
Number reporting a VCT for HCV	2,050	2,174	2,114	2,270		2,246		1,842	2,203	2,181	2,118	1,902	2,002
Total number answering question	2,745	2,906	2,757	2,794		2,719		2,229	2,654	2,664	2,561	2,217	2,378
Proportion aware of HCV infection	54%	52%	49%	51%		55%		50%	54%	47%	52%	53%	52%
Number aware of their HCV infection	590	594	506	596		667		473	650	570	596	544	589
Total number answering question	1,093	1,140	1,029	1,169		1,215		937	1,195	1,211	1,140	1,034	1,142
HIV VCT uptake	69%	68%	72%	74%		75%		77%	78%	75%	76%	78%	77%
Number reporting a VCT for HIV	1,914	2,014	2,000	2,090		2,076		1,780	2,163	1,996	1,898	1,706	1,820
Total number answering question	2,786	2,941	2,786	2,812		2,756		2,321	2,768	2,645	2,512	2,176	2,374
Among those who had injected in preceding year													
Symptom^{§§} of injection site infection	36%	39%	34%	36%		35%		27%	30%	28%	31%	32%	36%
Number reporting symptom ^{§§}	610	708	579	593		489		385	522	473	479	446	530
Total number answering question	1,718	1,825	1,716	1,646		1,381		1,416	1,766	1,703	1,569	1,413	1,480
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	23%	24%	19%	19%		21%		17%	14%	16%	16%	17%	18%
Number reporting direct sharing	413	449	316	315		337		202	216	228	220	198	224
Total number answering question	1,766	1,878	1,683	1,668		1,576		1,159	1,494	1,462	1,352	1,187	1,264
Level of sharing (direct & indirect) ††	47%	46%	39%	36%		39%		36%	35%	39%	38%	38%	40%
Number reporting sharing	829	888	649	609		614		415	521	570	522	453	517
Total number answering question	1,770	1,918	1,650	1,673		1,580		1,154	1,492	1,474	1,366	1,192	1,281
Proportion injecting crack	37%	37%	37%	31%		31%		35%	38%	39%	43%	51%	55%
Number reporting crack injection	651	708	630	519		489		400	566	588	596	616	713
Total number answering question	1,747	1,902	1,720	1,665		1,581		1,159	1,509	1,502	1,379	1,213	1,291
Proportion injecting into their groin	36%	33%	32%	36%		35%		35%	35%	39%	38%	38%	40%
Number reporting groin injection	597	619	549	597		546		415	527	587	527	456	526
Total number answering question	1,662	1,879	1,691	1,639		1,565		1,170	1,523	1,515	1,388	1,216	1,308
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	18%	19%	22%	20%		21%		18%	17%	18%	22%	21%	22%
Number always using a condom	146	162	180	154		163		124	146	111	122	102	95
Total number answering question	803	839	816	768		770		698	843	624	565	481	429

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 12: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE Region North: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016
Sample type	<i>Oral fluid*</i>	<i>Oral fluid*</i>	<i>Oral fluid*</i>	<i>Oral fluid*</i>	<i>DBS</i>	<i>Oral fluid*</i>	<i>DBS</i>	<i>DBS</i>	<i>DBS</i>	<i>DBS</i>	<i>DBS</i>	<i>DBS</i>	<i>DBS</i>
Anti-HIV Prevalence †	0.62%	0.55%	1.4%	1.5%		0.80%		0.77%	0.93%	0.20%	0.10%	0.25%	0.41%
Number of samples anti-HIV positive	6	5	12	13		9		7	10	2	1	2	4
Total number of samples collected	974	903	850	849		1,120		911	1,072	980	1,004	799	964
Anti-HBc Prevalence ††	30%	24%	19%	17%		19%		18%	17%	19%	15%	14%	17%
Proportion of samples anti-HBc positive	23%	18%	14%	14%	10%	11%	21%	18%	17%	19%	15%	14%	17%
Number of samples anti-HBc positive	220	160	121	96	17	45	151	168	182	190	155	113	166
Total number of samples collected	974	903	849	683	166	394	726	911	1,072	980	1,004	799	962
Anti-HCV Prevalence †††	49%	46%	47%	49%		51%		49%	52%	54%	52%	56%	58%
Proportion of samples anti-HCV positive	45%	43%	44%	45%	45%	38%	56%	49%	52%	54%	52%	56%	58%
Number of samples anti-HCV positive	443	385	371	310	75	151	409	450	555	525	524	448	560
Total number of samples collected	974	903	850	683	166	394	726	911	1,072	980	1,004	799	962
Hepatitis B vaccine uptake	72%	73%	78%	79%		78%		80%	78%	74%	73%	80%	76%
Number reporting hepatitis B vaccine uptake	687	641	651	665		861		693	815	699	701	609	688
Total number answering question	959	875	831	837		1,097		869	1,042	942	960	762	907
HCV VCT uptake	73%	74%	77%	81%		86%		85%	83%	80%	79%	86%	76%
Number reporting a VCT for HCV	672	618	619	648		902		667	797	745	757	656	777
Total number answering question	920	840	802	804		1,049		788	960	929	958	762	916
Proportion aware of HCV infection	40%	40%	49%	48%		52%		49%	52%	44%	51%	52%	48%
Number aware of their HCV infection	154	131	157	160		256		182	233	201	224	205	229
Total number answering question	389	329	320	335		493		370	448	457	443	395	475
HIV VCT uptake	63%	65%	68%	71%		75%		77%	76%	70%	70%	77%	73%
Number reporting a VCT for HIV	594	555	554	572		803		637	763	652	656	585	664
Total number answering question	943	849	812	810		1,067		828	1,004	928	939	759	915
Among those who had injected in preceding year													
Symptom^{§§} of injection site infection	32%	36%	31%	36%		35%		29%	29%	26%	31%	30%	38%
Number reporting symptom ^{§§}	179	189	147	172		182		135	180	143	170	138	205
Total number answering question	567	527	470	483		524		469	623	541	553	457	539
Among those who had injected in preceding four weeks													
Level of direct sharing †	23%	24%	18%	17%		20%		14%	15%	17%	16%	15%	17%
Number reporting direct sharing	138	134	83	83		123		54	81	81	75	60	77
Total number answering question	609	566	473	490		616		388	528	482	476	393	465
Level of sharing (direct & indirect) ††	44%	42%	36%	30%		36%		34%	35%	39%	39%	36%	43%
Number reporting sharing	267	242	169	148		223		133	187	190	186	141	202
Total number answering question	611	574	471	493		613		386	529	484	482	394	475
Proportion injecting crack	38%	36%	34%	22%		24%		26%	24%	34%	32%	43%	43%
Number reporting crack injection	232	207	165	108		146		99	132	168	155	173	205
Total number answering question	611	574	483	488		612		387	540	498	487	399	482
Proportion injecting into their groin	40%	33%	35%	38%		36%		41%	38%	45%	41%	45%	43%
Number reporting groin injection	225	184	170	181		218		159	207	227	199	180	208
Total number answering question	564	564	481	482		607		391	540	502	490	399	486
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	17%	19%	16%	16%		23%		17%	17%	15%	18%	23%	22%
Number always using a condom	43	48	38	38		66		43	53	34	32	35	36
Total number answering question	258	247	232	244		283		260	304	222	182	155	165

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 13: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE Region Midlands & East: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	0.63%	0.46%	0.73%	0.68%		0.31%		1.1%	1.1%	1.3%	1.0%	0.80%	1.4%
Number of samples anti-HIV positive	3	3	6	5		2		7	7	12	8	5	10
Total number of samples collected	478	655	818	738		639		635	654	910	773	626	716
Anti-HBc Prevalence ††	16%	8.8%	10%	8.4%		10%		11%	10%	11%	10%	10%	8%
Proportion of samples anti-HBc positive	12%	6.6%	7.2%	7.8%	4.3%	7.6%	10%	11%	10%	11%	10%	10%	8%
Number of samples anti-HBc positive	56	43	59	38	11	13	46	68	64	99	74	60	55
Total number of samples collected	478	655	818	485	253	171	468	635	654	910	773	626	714
Anti-HCV Prevalence †††	30%	31%	31%	41%		35%		35%	40%	45%	41%	43%	43%
Proportion of samples anti-HCV positive	28%	29%	29%	36%	44%	35%	35%	35%	40%	45%	41%	43%	43%
Number of samples anti-HCV positive	134	187	236	176	112	59	162	221	262	414	318	267	299
Total number of samples collected	478	655	818	485	253	171	468	635	654	910	773	626	695
Hepatitis B vaccine uptake	63%	67%	71%	74%		70%		77%	75%	69%	72%	71%	66%
Number reporting hepatitis B vaccine uptake	297	431	567	539		443		475	482	595	529	429	459
Total number answering question	473	644	799	731		632		618	641	866	731	602	694
HCV VCT uptake	65%	71%	74%	79%		74%		80%	78%	80%	82%	84%	82%
Number reporting a VCT for HCV	293	434	569	563		453		471	462	702	608	507	564
Total number answering question	449	614	770	713		614		589	589	875	743	604	692
Proportion aware of HCV infection	36%	39%	37%	45%		49%		39%	46%	44%	49%	55%	44%
Number aware of their HCV infection	43	65	73	119		98		74	100	155	133	119	113
Total number answering question	119	167	200	262		199		188	219	351	270	218	255
HIV VCT uptake	61%	62%	70%	71%		65%		74%	72%	73%	74%	74%	77%
Number reporting a VCT for HIV	278	386	548	507		399		444	447	633	536	433	537
Total number answering question	459	620	787	719		611		602	618	863	723	586	694
Among those who had injected in preceding year													
Symptom^{§§} of injection site infection	31%	37%	29%	28%		29%		24%	26%	27%	27%	31%	34%
Number reporting symptom ^{§§}	94	158	153	125		94		87	106	167	137	128	156
Total number answering question	305	425	528	439		324		361	414	619	502	411	454
Among those who had injected in preceding four weeks													
Level of direct sharing ‡	21%	20%	18%	16%		18%		14%	10%	14%	14%	15%	15%
Number reporting direct sharing	67	85	92	73		69		41	35	77	63	53	53
Total number answering question	326	434	521	446		376		283	352	551	441	360	355
Level of sharing (direct & indirect) ††	45%	41%	37%	36%		33%		32%	29%	34%	33%	33%	32%
Number reporting sharing	148	184	181	162		123		91	103	189	149	119	115
Total number answering question	329	445	487	446		376		283	351	555	445	361	355
Proportion injecting crack	33%	36%	26%	25%		29%		32%	41%	37%	37%	45%	48%
Number reporting crack injection	108	161	142	113		110		90	147	207	165	166	171
Total number answering question	329	451	540	445		378		284	356	561	446	371	354
Proportion injecting into their groin	34%	36%	34%	39%		32%		31%	39%	38%	38%	32%	37%
Number reporting groin injection	109	160	183	173		119		90	142	219	173	118	133
Total number answering question	325	447	531	439		372		286	361	572	454	369	360
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	18%	16%	22%	18%		21%		19%	14%	17%	25%	22%	27%
Number always using a condom	26	31	54	34		38		31	27	36	43	31	32
Total number answering question	146	193	247	194		179		165	189	217	172	139	117

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

‡ Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 14: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE Region South: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	0.71%	0.64%	0.74%	0.51%		0.83%		1.1%	0.73%	0.19%	0%	1.7%	0.2%
Number of samples anti-HIV positive	6	6	5	4		6		7	5	1	0	9	1
Total number of samples collected	848	933	679	784		722		659	683	515	504	530	499
Anti-HBc Prevalence ††	25%	20%	21%	18%		13%		15%	18%	17%	16%	14%	13%
Proportion of samples anti-HBc positive	19%	15%	16%	12%	26%	0%	13%	15%	18%	17%	16%	14%	13%
Number of samples anti-HBc positive	157	143	108	81	31	0	94	100	123	88	79	74	64
Total number of samples collected	848	933	679	667	117	14	708	659	683	515	504	530	499
Anti-HCV Prevalence †††	42%	42%	46%	48%		49%		47%	45%	46%	54%	53%	58%
Proportion of samples anti-HCV positive	38%	39%	42%	43%	56%	29%	49%	47%	45%	46%	54%	53%	58%
Number of samples anti-HCV positive	324	364	285	287	65	4	349	309	309	236	273	281	288
Total number of samples collected	848	933	679	667	117	14	708	659	683	515	504	530	499
Hepatitis B vaccine uptake	60%	58%	70%	69%		76%		75%	72%	69%	72%	74%	68%
Number reporting hepatitis B vaccine uptake	498	529	467	531		538		484	476	339	347	372	332
Total number answering question	834	910	665	771		705		647	662	492	484	505	485
HCV VCT uptake	75%	72%	75%	80%		82%		83%	82%	84%	88%	87%	84%
Number reporting a VCT for HCV	608	644	497	605		574		511	514	419	431	447	410
Total number answering question	815	890	659	755		698		616	624	496	489	513	490
Proportion aware of HCV infection	60%	55%	44%	46%		54%		57%	54%	47%	54%	49%	56%
Number aware of their HCV infection	174	178	115	144		175		154	140	94	126	119	142
Total number answering question	292	325	260	312		322		272	257	202	235	244	253
HIV VCT uptake	70%	68%	72%	77%		78%		79%	82%	80%	80%	82%	77%
Number reporting a VCT for HIV	574	617	478	577		553		504	528	394	386	410	372
Total number answering question	820	905	662	754		709		634	646	492	483	500	484
Among those who had injected in preceding year													
Symptom^{§§} of injection site infection	40%	40%	39%	40%		40%		26%	28%	26%	32%	38%	34%
Number reporting symptom ^{§§}	229	237	178	193		162		119	120	90	110	138	120
Total number answering question	572	592	460	486		406		466	436	349	349	366	352
Among those who had injected in preceding four weeks													
Level of direct sharing †	26%	27%	21%	24%		25%		22%	17%	17%	20%	22%	23%
Number reporting direct sharing	147	161	97	118		107		86	64	48	65	67	77
Total number answering question	566	607	463	493		431		392	381	285	319	310	333
Level of sharing (direct & indirect) ††	51%	51%	45%	44%		47%		41%	39%	48%	47%	47%	49%
Number reporting sharing	286	316	210	219		203		161	150	139	150	149	166
Total number answering question	564	622	467	497		436		389	381	291	322	314	338
Proportion injecting crack	34%	32%	45%	37%		37%		41%	42%	44%	65%	63%	76%
Number reporting crack injection	192	200	210	183		160		160	160	129	209	201	257
Total number answering question	569	622	469	496		438		391	379	296	324	318	338
Proportion injecting into their groin	38%	33%	34%	36%		36%		33%	30%	35%	37%	40%	42%
Number reporting groin injection	202	199	158	178		157		131	116	102	117	127	144
Total number answering question	538	606	459	490		436		394	386	294	320	321	342
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	18%	16%	18%	21%		17%		18%	11%	15%	15%	19%	14%
Number always using a condom	48	44	37	47		39		38	25	17	21	23	14
Total number answering question	273	269	203	227		231		206	223	113	136	119	99

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested) x 100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS) x 100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS) x 100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 15: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; PHE & NUTS Region London: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009	2010		2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	4.0%	3.9%	3.8%	4.1%	4.3%		3.9%	3.7%	4.5%	4.7%	2.0%	2.1%
Number of samples anti-HIV positive	24	23	21	24	18		11	21	17	18	7	6
Total number of samples collected	593	594	546	591	418		280	573	377	386	352	290
Anti-HBc Prevalence ††	45%	36%	28%	32%	33%		24%	28%	28%	25%	20%	27%
Proportion of samples anti-HBc positive	34%	27%	21%	24%	28%	22%	24%	28%	28%	25%	20%	27%
Number of samples anti-HBc positive	201	160	114	140	84	26	68	159	104	96	72	74
Total number of samples collected	593	594	546	591	302	116	280	573	377	386	352	276
Anti-HCV Prevalence †††	61%	65%	57%	59%	64%		48%	59%	59%	60%	55%	63%
Proportion of samples anti-HCV positive	56%	60%	52%	54%	60%	61%	48%	59%	59%	60%	55%	63%
Number of samples anti-HCV positive	332	356	285	319	181	71	135	340	223	230	195	174
Total number of samples collected	593	594	546	591	302	116	280	573	377	386	352	276
Hepatitis B vaccine uptake	62%	66%	66%	69%	73%		70%	73%	75%	67%	71%	76%
Number reporting hepatitis B vaccine uptake	356	381	354	382	278		192	396	270	238	234	203
Total number answering question	573	579	533	554	382		274	541	362	357	329	267
HCV VCT uptake	85%	85%	82%	87%	89%		82%	89%	87%	87%	86%	90%
Number reporting a VCT for HCV	477	478	429	454	317		193	430	315	322	292	251
Total number answering question	561	562	526	522	358		236	481	364	371	338	280
Proportion aware of HCV infection	75%	69%	65%	67%	69%		59%	65%	60%	59%	57%	66%
Number aware of their HCV infection	219	220	161	173	138		63	177	120	113	101	105
Total number answering question	293	319	249	260	201		107	271	201	192	177	159
HIV VCT uptake	83%	80%	80%	82%	87%		76%	85%	88%	87%	84%	88%
Number reporting a VCT for HIV	468	456	420	434	321		195	425	317	320	278	247
Total number answering question	564	567	525	529	369		257	500	362	367	331	281
Among those who had injected in preceding year												
Symptom^{§§} of injection site infection	39%	44%	39%	43%	40%		37%	40%	38%	38%	23%	36%
Number reporting symptom ^{§§}	108	124	101	103	51		44	116	73	62	42	49
Total number answering question	274	281	258	238	127		120	293	194	165	179	135
Among those who had injected in preceding four weeks												
Level of direct sharing †	23%	25%	19%	17%	25%		22%	15%	15%	15%	15%	15%
Number reporting direct sharing	61	69	44	41	38		21	36	22	17	18	17
Total number answering question	265	271	226	239	153		96	233	144	116	124	111
Level of sharing (direct & indirect) ††	48%	53%	40%	34%	42%		31%	35%	36%	32%	36%	30%
Number reporting sharing	128	146	89	80	65		30	81	52	37	44	34
Total number answering question	266	277	225	237	155		96	231	144	117	123	113
Proportion injecting crack	50%	55%	50%	49%	48%		53%	54%	57%	55%	61%	68%
Number reporting crack injection	119	140	113	115	73		51	127	84	67	76	80
Total number answering question	238	255	228	236	153		97	234	147	122	125	117
Proportion injecting into their groin	26%	29%	17%	29%	35%		35%	26%	27%	31%	24%	34%
Number reporting groin injection	61	76	38	65	52		35	62	39	38	31	41
Total number answering question	235	262	220	228	150		99	236	147	124	127	120
Among those with two or more (anal or vaginal) sexual partners in preceding year												
Proportion always using a condom	23%	30%	38%	34%	26%		18%	32%	33%	35%	19%	27%
Number always using a condom	29	39	51	35	20		12	41	24	26	13	13
Total number answering question	126	130	134	103	77		67	127	72	75	68	48

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 16: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region East of England: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	0.58%	0.91%	0.84%	0.75%	0%	0.65%	0%	1.7%	0%	0%	0.44%
Number of samples anti-HIV positive	1	1	2	1	0	1	0	3	0	0	1
Total number of samples collected	172	110	238	134	119	153	145	176	163	241	226
Anti-HBc Prevalence ††	24%	15%	16%	18%	10%	18%	10%	11%	13%	10%	9%
Proportion of samples anti-HBc positive	18%	11%	12%	13%	7.6%	18%	10%	11%	13%	10%	9%
Number of samples anti-HBc positive	31	12	29	18	9	27	14	19	22	23	20
Total number of samples collected	172	110	238	134	119	153	145	176	163	241	225
Anti-HCV Prevalence †††	28%	38%	34%	48%	34%	41%	37%	46%	39%	46%	43%
Proportion of samples anti-HCV positive	26%	35%	32%	44%	31%	41%	37%	46%	39%	46%	43%
Number of samples anti-HCV positive	44	38	75	59	37	63	53	81	63	110	96
Total number of samples collected	172	110	238	134	119	153	145	176	163	241	225
Hepatitis B vaccine uptake	64%	61%	73%	79%	63%	74%	74%	65%	72%	69%	65%
Number reporting hepatitis B vaccine uptake	109	63	171	104	75	109	106	106	103	158	143
Total number answering question	170	104	235	132	119	148	143	163	143	230	220
HCV VCT uptake	68%	76%	76%	85%	74%	88%	69%	80%	77%	76%	78%
Number reporting a VCT for HCV	110	74	170	111	86	128	92	137	119	175	170
Total number answering question	162	98	223	131	117	146	134	171	154	229	217
Proportion aware of HCV infection	55%	44%	37%	58%	53%	57%	33%	47%	47%	49%	51%
Number aware of their HCV infection	22	16	22	31	18	31	15	32	25	39	43
Total number answering question	40	36	59	53	34	54	45	68	53	79	84
HIV VCT uptake	68%	69%	74%	76%	70%	84%	70%	77%	73%	65%	73%
Number reporting a VCT for HIV	112	67	169	100	81	123	97	132	110	143	159
Total number answering question	165	97	228	131	115	147	138	171	150	221	217
Among those who had injected in preceding year											
Symptom^{§§} of injection site infection	27%	48%	34%	25%	34%	23%	24%	27%	25%	37%	38%
Number reporting symptom ^{§§}	25	24	42	17	21	18	22	34	20	60	57
Total number answering question	93	50	124	69	61	78	92	127	79	161	151
Among those who had injected in preceding four weeks											
Level of direct sharing †	21%	21%	22%	27%	29%	15%	5.5%	12%	12%	16%	17%
Number reporting direct sharing	14	11	23	12	24	8	4	11	7	23	19
Total number answering question	66	53	106	45	83	52	73	93	60	142	115
Level of sharing (direct & indirect) ††	42%	48%	42%	42%	45%	35%	22%	38%	31%	39%	36%
Number reporting sharing	28	26	46	19	37	18	16	36	19	56	41
Total number answering question	67	54	109	45	83	52	73	94	61	142	115
Proportion injecting crack	22%	35%	21%	24%	24%	40%	39%	38%	43%	46%	50%
Number reporting crack injection	15	19	23	11	20	21	28	36	26	68	58
Total number answering question	68	54	109	46	82	53	72	96	61	147	116
Proportion injecting into their groin	28%	21%	30%	33%	17%	32%	37%	38%	34%	36%	33%
Number reporting groin injection	18	12	32	15	13	17	27	38	21	52	39
Total number answering question	65	57	106	46	78	53	73	99	62	146	118
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	17%	18%	36%	17%	42%	26%	25%	7.7%	26%	20%	24%
Number always using a condom	8	6	27	6	16	10	11	4	8	12	9
Total number answering question	47	34	74	35	38	38	44	52	31	60	37

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 17: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region South East: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	0.75%	1.1%	0.88%	0.76%		1.2%		1.8%	1.0%	0.46%	0%	1.8%	0.0%
Number of samples anti-HIV positive	3	6	4	4		5		6	3	1	0	5	0
Total number of samples collected	400	548	452	524		428		337	300	217	237	271	275
Anti-HBc Prevalence ††	24%	19%	24%	18%		17%		19%	25%	18%	20%	18%	9.1%
Proportion of samples anti-HBc positive	18%	15%	18%	12%	26%	0%	17%	19%	25%	18%	20%	18%	9%
Number of samples anti-HBc positive	73	80	80	49	31	0	71	64	74	40	48	48	25
Total number of samples collected	400	548	452	407	117	14	414	337	300	217	237	271	275
Anti-HCV Prevalence †††	41%	47%	51%	52%		57%		54%	58%	54%	58%	58%	50%
Proportion of samples anti-HCV positive	38%	43%	46%	47%	56%	29%	57%	54%	58%	54%	58%	58%	50%
Number of samples anti-HCV positive	152	238	210	191	65	4	238	181	174	118	137	158	138
Total number of samples collected	400	548	452	407	117	14	414	337	300	217	237	271	275
Hepatitis B vaccine uptake	56%	57%	70%	71%		75%		77%	73%	74%	73%	73%	67%
Number reporting hepatitis B vaccine uptake	221	302	308	364		314		256	218	151	168	185	181
Total number answering question	392	532	442	512		420		332	297	204	229	255	271
HCV VCT uptake	73%	72%	77%	80%		81%		85%	83%	87%	90%	88%	80%
Number reporting a VCT for HCV	286	373	337	405		344		272	235	181	209	229	216
Total number answering question	390	518	437	504		424		320	282	208	231	260	270
Proportion aware of HCV infection	59%	57%	47%	44%		53%		59%	60%	50%	50%	44%	56%
Number aware of their HCV infection	82	121	90	99		121		97	90	53	60	61	71
Total number answering question	138	214	193	225		227		165	151	106	120	138	126
HIV VCT uptake	69%	69%	74%	78%		77%		83%	82%	81%	83%	81%	75%
Number reporting a VCT for HIV	270	363	326	393		330		270	237	170	185	202	197
Total number answering question	390	529	441	504		427		326	289	210	224	249	264
Among those who had injected in preceding year													
Symptom^{§§} of injection site infection	42%	38%	39%	40%		41%		25%	31%	28%	34%	34%	35%
Number reporting symptom ^{§§}	121	131	121	129		107		62	69	43	54	62	58
Total number answering question	288	346	311	319		258		247	222	153	159	183	167
Among those who had injected in preceding four weeks													
Level of direct sharing †	26%	28%	21%	26%		21%		21%	14%	14%	18%	21%	24%
Number reporting direct sharing	71	99	67	85		59		47	28	19	27	35	36
Total number answering question	276	354	315	328		277		220	201	137	152	165	148
Level of sharing (direct & indirect) ††	56%	55%	48%	47%		44%		37%	34%	41%	37%	45%	50%
Number reporting sharing	155	199	154	154		125		81	67	57	57	74	74
Total number answering question	277	361	318	329		282		219	199	138	154	166	149
Proportion injecting crack	42%	37%	49%	40%		43%		46%	46%	54%	65%	60%	68%
Number reporting crack injection	118	131	155	132		121		102	92	75	102	100	102
Total number answering question	280	357	318	329		282		222	199	140	157	166	149
Proportion injecting into their groin	34%	31%	33%	38%		36%		33%	28%	29%	37%	37%	36%
Number reporting groin injection	92	110	104	122		101		73	56	41	57	63	54
Total number answering question	269	350	312	325		283		223	202	139	155	169	150
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	12%	18%	17%	25%		15%		21%	12%	10%	15%	18%	9%
Number always using a condom	16	27	24	40		20		20	11	4	9	10	5
Total number answering question	135	151	139	159		136		97	93	40	61	57	54

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 18: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region South West: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	0.67%	0%	0.44%	0%	0.34%	0.31%	0.52%	0%	0%	1.5%	0.4%
Number of samples anti-HIV positive	3	0	1	0	1	1	2	0	0	4	1
Total number of samples collected	448	385	227	260	294	322	383	298	267	259	224
Anti-HBc Prevalence ††	25%	22%	16%	16%	7.8%	11%	13%	16%	12%	10%	17%
Proportion of samples anti-HBc positive	19%	16%	12%	12%	7.8%	11%	13%	16%	12%	10%	17%
Number of samples anti-HBc positive	84	63	28	32	23	36	49	48	31	26	39
Total number of samples collected	448	385	227	260	294	322	383	298	267	259	224
Anti-HCV Prevalence †††	42%	36%	36%	40%	38%	40%	35%	40%	51%	47%	67%
Proportion of samples anti-HCV positive	38%	33%	33%	37%	38%	40%	35%	40%	51%	47%	67%
Number of samples anti-HCV positive	172	126	75	96	111	128	135	118	136	123	150
Total number of samples collected	448	385	227	260	294	322	383	298	267	259	224
Hepatitis B vaccine uptake	63%	60%	71%	64%	79%	72%	71%	65%	70%	75%	71%
Number reporting hepatitis B vaccine uptake	277	227	159	167	224	228	258	188	179	187	151
Total number answering question	442	378	223	259	285	315	365	288	255	250	214
HCV VCT uptake	76%	73%	72%	80%	84%	81%	82%	83%	86%	86%	88%
Number reporting a VCT for HCV	322	271	160	200	230	239	279	238	222	218	194
Total number answering question	425	372	222	251	274	296	342	288	258	253	220
Proportion aware of HCV infection	60%	51%	37%	52%	57%	53%	47%	43%	57%	55%	56%
Number aware of their HCV infection	92	57	25	45	54	57	50	41	66	58	71
Total number answering question	154	111	67	87	95	107	106	96	115	106	127
HIV VCT uptake	71%	68%	69%	74%	79%	76%	82%	79%	78%	83%	80%
Number reporting a VCT for HIV	304	254	152	184	223	234	291	224	201	208	175
Total number answering question	430	376	221	250	282	308	357	282	259	251	220
Among those who had injected in preceding year											
Symptom^{§§} of injection site infection	38%	43%	38%	38%	37%	26%	24%	24%	29%	42%	34%
Number reporting symptom ^{§§}	108	106	57	64	55	57	51	47	56	76	62
Total number answering question	284	246	149	167	148	219	214	196	190	183	185
Among those who had injected in preceding four weeks											
Level of direct sharing †	26%	25%	20%	20%	31%	23%	20%	20%	23%	22%	22%
Number reporting direct sharing	76	62	30	33	48	39	36	29	38	32	41
Total number answering question	290	253	148	165	154	172	180	148	167	145	185
Level of sharing (direct & indirect) ††	46%	45%	38%	39%	51%	47%	46%	54%	55%	51%	49%
Number reporting sharing	131	117	56	65	78	80	83	82	93	75	92
Total number answering question	287	261	149	168	154	170	182	153	168	148	189
Proportion injecting crack	26%	26%	36%	31%	25%	34%	38%	35%	64%	66%	82%
Number reporting crack injection	74	69	55	51	39	58	68	54	107	101	155
Total number answering question	289	265	151	167	156	169	180	156	167	152	189
Proportion injecting into their groin	41%	35%	37%	34%	37%	34%	33%	39%	36%	42%	47%
Number reporting groin injection	110	89	54	56	56	58	60	61	60	64	90
Total number answering question	269	256	147	165	153	171	184	155	165	152	192
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	23%	14%	20%	10%	20%	17%	11%	18%	16%	21%	20%
Number always using a condom	32	17	13	7	19	18	14	13	12	13	9
Total number answering question	138	118	64	68	95	109	130	73	75	62	45

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 19: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region West Midlands: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2005	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	1.4%	0.43%	0.43%	0%	0%		0%		1.4%	1.8%	1.5%	0%	0%	1%
Number of samples anti-HIV positive	2	1	1	0	0		0		4	4	6	0	0	3
Total number of samples collected	145	235	231	315	291		276		276	228	412	291	154	273
Anti-HBc Prevalence ††	7.4%	6.2%	5.2%	7.7%		6.3%		8.3%	7.0%	10%	5.2%	3.2%	5.1%	
Proportion of samples anti-HBc positive	5.5%	4.7%	3.9%	7.7%	2.8%	7.7%	5.4%	8.3%	7.0%	10%	5.2%	3.2%	5.1%	
Number of samples anti-HBc positive	8	11	9	16	3	4	13	23	16	43	15	5	14	
Total number of samples collected	145	235	231	207	108	52	239	276	228	412	291	154	273	
Anti-HCV Prevalence †††	23%	30%	29%	36%		28%		33%	37%	42%	36%	26%	39%	
Proportion of samples anti-HCV positive	21%	28%	26%	34%	33%	42%	24%	33%	37%	42%	36%	26%	39%	
Number of samples anti-HCV positive	31	65	61	70	36	22	57	90	84	174	104	40	99	
Total number of samples collected	145	235	231	207	108	52	239	276	228	412	291	154	254	
Hepatitis B vaccine uptake	53%	61%	59%	67%		65%		76%	71%	64%	69%	71%	62%	
Number reporting hepatitis B vaccine uptake	76	142	130	209		187		204	160	257	195	108	163	
Total number answering question	144	234	222	312		287		270	224	401	282	153	263	
HCV VCT uptake	57%	70%	64%	71%		64%		73%	76%	77%	80%	86%	80%	
Number reporting a VCT for HCV	79	154	138	217		181		190	156	314	224	129	215	
Total number answering question	139	221	215	306		284		259	204	406	281	150	268	
Proportion aware of HCV infection	23%	45%	38%	46%		44%		29%	53%	46%	55%	53%	40%	
Number aware of their HCV infection	7	27	21	45		32		22	38	68	45	18	33	
Total number answering question	30	60	56	97		73		77	72	149	82	34	83	
HIV VCT uptake	55%	64%	66%	68%		61%		72%	75%	70%	74%	78%	77%	
Number reporting a VCT for HIV	78	145	147	211		172		191	164	276	207	116	207	
Total number answering question	141	225	224	309		284		265	220	393	279	149	269	
Among those who had injected in preceding year														
Symptom^{§§} of injection site infection			34%	34%	34%		26%		24%	23%	29%	26%	26%	35%
Number reporting symptom ^{§§}			57	49	57		31		33	30	73	49	25	62
Total number answering question			167	145	166		119		136	131	256	185	97	175
Among those who had injected in preceding four weeks														
Level of direct sharing †	21%	18%	13%	16%		12%		13%	11%	15%	15%	4.0%	16%	
Number reporting direct sharing	24	31	21	32		16		13	12	36	23	3	23	
Total number answering question	114	168	157	194		131		97	106	233	151	75	141	
Level of sharing (direct & indirect) ††	43%	39%	30%	31%		25%		32%	28%	32%	37%	25%	35%	
Number reporting sharing	49	68	47	60		33		31	29	74	57	19	49	
Total number answering question	115	173	157	194		131		97	105	234	153	75	140	
Proportion injecting crack			43%	35%	33%		24%		34%	54%	45%	35%	33%	41%
Number reporting crack injection			75	57	64		31		32	58	107	54	25	56
Total number answering question			174	163	193		130		95	107	237	155	76	138
Proportion injecting into their groin			41%	34%	40%		35%		32%	35%	38%	31%	32%	35%
Number reporting groin injection			70	56	77		46		30	38	92	48	24	50
Total number answering question			172	164	192		130		95	110	244	157	76	141
Among those with two or more (anal or vaginal) sexual partners in preceding year														
Proportion always using a condom	15%	22%	17%	24%		22%		23%	14%	21%	27%	27%	28%	
Number always using a condom	7	17	11	21		17		16	9	19	16	8	13	
Total number answering question	48	76	64	89		78		71	65	92	60	30	46	

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 20: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region North West: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	1.1%	0.82%	2.6%	2.3%		1.8%		1.8%	2.2%	0%	0%	0.48%	0.61%
Number of samples anti-HIV positive	6	4	11	10		8		7	9	0	0	2	3
Total number of samples collected	553	489	427	428		434		397	409	379	383	414	495
Anti-HBc Prevalence ††	43%	34%	29%	25%		27%		28%	29%	32%	27%	23%	23%
Proportion of samples anti-HBc positive	32%	26%	22%	18%	26%	24%	26%	28%	29%	32%	27%	23%	23%
Number of samples anti-HBc positive	178	126	94	72	9	20	91	110	117	122	102	94	114
Total number of samples collected	553	489	426	393	35	84	350	397	409	379	383	414	495
Anti-HCV Prevalence †††	67%	64%	63%	62%		65%		60%	64%	68%	66%	68%	67%
Proportion of samples anti-HCV positive	61%	59%	58%	56%	63%	68%	63%	60%	64%	68%	66%	68%	67%
Number of samples anti-HCV positive	340	288	246	222	22	57	219	239	263	258	251	281	333
Total number of samples collected	553	489	427	393	35	84	350	397	409	379	383	414	495
Hepatitis B vaccine uptake	68%	68%	75%	74%		75%		81%	77%	71%	70%	81%	77%
Number reporting hepatitis B vaccine uptake	371	323	311	313		320		316	310	258	256	327	360
Total number answering question	545	477	417	423		429		389	401	362	367	402	469
HCV VCT uptake	75%	76%	81%	82%		86%		88%	85%	78%	81%	90%	86%
Number reporting a VCT for HCV	393	347	333	342		355		311	303	283	297	359	407
Total number answering question	523	456	410	415		413		352	356	363	366	400	471
Proportion aware of HCV infection	42%	41%	49%	52%		54%		56%	56%	44%	57%	52%	49%
Number aware of their HCV infection	127	103	103	114		140		111	110	98	123	129	138
Total number answering question	299	251	210	218		258		199	197	223	215	250	281
HIV VCT uptake	62%	66%	73%	72%		79%		81%	79%	65%	69%	80%	73%
Number reporting a VCT for HIV	333	306	301	295		332		306	306	233	250	317	347
Total number answering question	537	466	412	412		420		379	388	356	361	395	474
Among those who had injected in preceding year													
Symptom^{§§} of injection site infection	35%	40%	37%	37%		32%		25%	31%	23%	28%	32%	39%
Number reporting symptom ^{§§}	106	114	88	88		59		50	58	39	54	65	104
Total number answering question	303	287	236	236		185		199	187	171	191	205	266
Among those who had injected in preceding four weeks													
Level of direct sharing †	23%	21%	16%	13%		15%		11%	12%	14%	14%	15%	11%
Number reporting direct sharing	76	60	36	30		26		18	20	21	22	27	24
Total number answering question	330	285	226	228		179		162	161	145	156	181	214
Level of sharing (direct & indirect) ††	49%	44%	39%	28%		29%		29%	30%	34%	38%	34%	39%
Number reporting sharing	161	129	89	65		52		47	49	50	60	61	86
Total number answering question	331	292	227	229		179		160	161	146	157	180	220
Proportion injecting crack	55%	53%	56%	36%		28%		31%	32%	48%	50%	54%	54%
Number reporting crack injection	183	152	127	80		51		49	53	72	80	98	122
Total number answering question	330	287	226	224		179		160	165	150	159	183	224
Proportion injecting into their groin	47%	38%	41%	46%		40%		44%	38%	45%	42%	46%	42%
Number reporting groin injection	138	106	93	105		71		71	64	67	67	84	94
Total number answering question	292	279	226	226		179		162	168	150	159	181	226
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	19%	27%	21%	21%		26%		26%	27%	15%	28%	26%	24%
Number always using a condom	23	34	20	22		26		25	24	11	17	18	17
Total number answering question	119	124	94	106		99		98	90	74	60	69	71

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested) x 100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive / 0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS) x 100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive / 0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS) x 100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 21: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region Yorkshire & Humber: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009	2010		2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	0%	0%	0%	0%	0%	0%	0%	0%	0.29%	0.25%	0%	0%
Number of samples anti-HIV positive	0	0	0	0	0	0	0	0	1	1	0	1
Total number of samples collected	148	113	261	402	297	299	341	396	228	270		
Anti-HBc Prevalence ††	7.2%	9.4%	6.6%	16%	11%	8.7%	12%	8.8%	4.4%	14%		
Proportion of samples anti-HBc positive	5.4%	7.1%	5.0%	4.6%	18%	11%	8.7%	12%	8.8%	4.4%	14%	
Number of samples anti-HBc positive	8	8	13	4	58	34	26	42	35	10	38	
Total number of samples collected	148	113	261	87	315	297	299	341	396	228	270	
Anti-HCV Prevalence †††	32%	38%	42%	52%	47%	57%	50%	52%	48%	57%		
Proportion of samples anti-HCV positive	29%	35%	39%	51%	52%	47%	57%	50%	52%	48%	57%	
Number of samples anti-HCV positive	43	39	102	44	163	140	171	172	207	110	153	
Total number of samples collected	148	113	261	87	315	297	299	341	396	228	270	
Hepatitis B vaccine uptake	76%	79%	80%	76%	78%	83%	77%	78%	78%	79%		
Number reporting hepatitis B vaccine uptake	110	81	207	300	215	237	257	292	164	194		
Total number answering question	145	102	258	394	276	286	332	374	211	245		
HCV VCT uptake	68%	74%	76%	85%	81%	84%	82%	82%	81%	88%		
Number reporting a VCT for HCV	92	67	184	320	205	238	265	307	173	221		
Total number answering question	135	91	243	375	252	285	322	376	213	252		
Proportion aware of HCV infection	32%	56%	56%	51%	46%	57%	49%	49%	63%	55%		
Number aware of their HCV infection	12	14	45	89	51	88	71	85	60	72		
Total number answering question	38	25	80	173	111	154	146	173	96	130		
HIV VCT uptake	66%	57%	59%	68%	72%	75%	72%	72%	74%	77%		
Number reporting a VCT for HIV	89	52	143	257	188	207	234	263	158	189		
Total number answering question	135	91	243	378	262	276	326	366	214	246		
Among those who had injected in preceding year												
Symptom^{§§} of injection site infection	31%	46%	28%	35%	37%	29%	26%	34%	34%	38%		
Number reporting symptom ^{§§}	19	17	29	61	48	56	52	72	48	54		
Total number answering question	61	37	102	174	131	193	202	211	141	141		
Among those who had injected in preceding four weeks												
Level of direct sharing †	13%	38%	18%	23%	12%	17%	14%	13%	15%	19%		
Number reporting direct sharing	7	11	16	54	13	27	25	23	17	22		
Total number answering question	54	29	88	230	107	157	179	183	115	114		
Level of sharing (direct & indirect) ††	30%	60%	34%	45%	38%	40%	41%	36%	44%	43%		
Number reporting sharing	16	18	30	102	41	63	73	67	51	49		
Total number answering question	54	30	88	225	107	157	179	188	117	115		
Proportion injecting crack	60%	60%	51%	33%	44%	41%	43%	35%	56%	61%		
Number reporting crack injection	32	18	45	75	47	65	78	67	67	70		
Total number answering question	53	30	89	225	107	160	183	189	119	114		
Proportion injecting into their groin	31%	23%	36%	42%	45%	45%	49%	41%	48%	43%		
Number reporting groin injection	16	7	32	96	48	71	92	78	57	49		
Total number answering question	51	30	89	226	107	159	187	190	119	115		
Among those with two or more (anal or vaginal) sexual partners in preceding year												
Proportion always using a condom	13%	13%	12%	21%	15%	15%	16%	17%	26%	19%		
Number always using a condom	5	3	8	21	13	12	13	11	12	9		
Total number answering question	40	23	67	100	85	82	80	66	47	48		

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 22: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region East Midlands: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009		2010	2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	0%	0.32%	0.86%	1.4%		0.87%	0.97%	1.1%	0.93%	2.5%	2.2%	2.8%
Number of samples anti-HIV positive	0	1	3	4		2	2	3	3	8	5	6
Total number of samples collected	182	310	349	289		229	206	281	322	319	231	217
Anti-HBc Prevalence ††	13%	8.6%	8.0%	4.6%		14%	8.7%	12%	11%	12%	14%	10%
Proportion of samples anti-HBc positive	10%	6.5%	6.0%	2.8%	5.5%	14%	8.7%	12%	11%	12%	14%	10%
Number of samples anti-HBc positive	18	20	21	4	8	33	18	34	37	37	32	21
Total number of samples collected	182	310	349	144	145	229	206	281	322	319	231	216
Anti-HCV Prevalence †††	41%	29%	31%	44%		46%	33%	44%	49%	47%	51%	48%
Proportion of samples anti-HCV positive	37%	27%	29%	33%	52%	46%	33%	44%	49%	47%	51%	48%
Number of samples anti-HCV positive	68	84	100	47	76	105	68	125	159	151	117	104
Total number of samples collected	182	310	349	144	145	229	206	281	322	319	231	216
Hepatitis B vaccine uptake	68%	74%	78%	79%		80%	81%	79%	77%	75%	74%	73%
Number reporting hepatitis B vaccine uptake	122	226	266	226		181	162	216	232	231	163	153
Total number answering question	180	306	342	287		226	200	274	302	306	219	211
HCV VCT uptake	69%	70%	79%	85%		87%	83%	85%	84%	86%	90%	86%
Number reporting a VCT for HCV	117	206	261	235		186	153	214	251	265	203	179
Total number answering question	169	295	332	276		213	184	251	298	308	225	207
Proportion aware of HCV infection	28%	31%	35%	38%		52%	37%	46%	41%	47%	59%	42%
Number aware of their HCV infection	16	22	30	43		48	21	47	55	63	62	37
Total number answering question	57	71	85	112		92	57	102	134	135	105	88
HIV VCT uptake	60%	58%	69%	70%		69%	68%	72%	75%	74%	81%	82%
Number reporting a VCT for HIV	104	174	232	196		146	130	186	225	219	174	171
Total number answering question	174	298	335	279		212	190	260	299	294	216	208
Among those who had injected in preceding year												
Symptom^{§§} of injection site infection	33%	37%	24%	25%		29%	24%	28%	25%	29%	28%	29%
Number reporting symptom ^{§§}	45	77	62	51		42	36	54	60	68	43	37
Total number answering question	137	208	259	204		144	147	191	236	238	153	128
Among those who had injected in preceding four weeks												
Level of direct sharing †	20%	20%	19%	14%		18%	15%	11%	13%	14%	19%	11%
Number reporting direct sharing	33	43	48	29		29	20	19	30	33	27	11
Total number answering question	162	213	258	207		162	134	173	225	230	143	99
Level of sharing (direct & indirect) ††	48%	41%	40%	40%		33%	31%	34%	35%	32%	31%	25%
Number reporting sharing	79	90	88	83		53	42	58	79	73	44	25
Total number answering question	163	218	221	207		162	134	173	227	231	144	100
Proportion injecting crack	33%	30%	23%	18%		36%	27%	34%	28%	37%	49%	57%
Number reporting crack injection	54	67	62	38		59	37	61	64	85	73	57
Total number answering question	163	223	268	206		166	136	177	228	230	148	100
Proportion injecting into their groin	41%	36%	36%	40%		37%	31%	43%	39%	44%	29%	44%
Number reporting groin injection	67	78	95	81		60	43	77	89	104	42	44
Total number answering question	164	218	261	201		164	138	178	229	235	147	101
Among those with two or more (anal or vaginal) sexual partners in preceding year												
Proportion always using a condom	22%	10%	15%	10%		7.9%	8.9%	8.8%	18%	23%	22%	29%
Number always using a condom	14	8	16	7		5	5	7	13	19	11	10
Total number answering question	63	83	109	70		63	56	80	73	81	49	34

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested) x 100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive / 0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS) x 100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive / 0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS) x 100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 23: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; NUTS Region North East: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	0%	0.33%	0.40%	0.91%		0.35%		0%	0.27%	0.38%	0%	0%	0%
Number of samples anti-HIV positive	0	1	1	3		1		0	1	1	0	0	0
Total number of samples collected	273	301	252	331		284		217	364	260	225	157	199
Anti-HBc Prevalence ††	17%	12%	11%	10%		11%		11%	11%	10%	8.0%	5.7%	7.1%
Proportion of samples anti-HBc positive	12%	8.6%	7.9%	9.0%	6.1%	9.4%	3.3%	11%	11%	10%	8.0%	5.7%	7.1%
Number of samples anti-HBc positive	34	26	20	18	8	21	2	24	39	26	18	9	14
Total number of samples collected	273	301	252	200	131	223	61	217	364	260	225	157	197
Anti-HCV Prevalence †††	24%	21%	25%	33%		29%		33%	33%	37%	29%	36%	38%
Proportion of samples anti-HCV positive	22%	19%	23%	26%	40%	22%	44%	33%	33%	37%	29%	36%	38%
Number of samples anti-HCV positive	60	58	59	52	53	50	27	71	121	95	66	57	74
Total number of samples collected	273	301	252	200	131	223	61	217	364	260	225	157	197
Hepatitis B vaccine uptake	77%	80%	83%	87%		88%		79%	75%	74%	70%	79%	69%
Number reporting hepatitis B vaccine uptake	206	237	203	282		241		162	268	184	153	118	134
Total number answering question	269	296	246	324		274		204	355	248	219	149	193
HCV VCT uptake	71%	70%	74%	77%		87%		82%	80%	81%	71%	83%	77%
Number reporting a VCT for HCV	187	204	172	236		227		151	256	197	153	124	149
Total number answering question	262	293	233	305		261		184	319	244	216	149	193
Proportion aware of HCV infection	29%	26%	43%	34%		44%		33%	36%	36%	29%	33%	30%
Number aware of their HCV infection	15	14	23	32		27		20	35	32	16	16	19
Total number answering question	52	53	54	93		62		60	97	88	55	49	64
HIV VCT uptake	63%	67%	68%	71%		80%		76%	74%	75%	67%	73%	66%
Number reporting a VCT for HIV	172	197	161	226		214		143	250	185	143	110	128
Total number answering question	271	292	238	317		269		187	340	246	212	150	195
Among those who had injected in preceding year													
Symptom^{§§} of injection site infection	27%	29%	24%	35%		38%		27%	27%	31%	29%	23%	36%
Number reporting symptom ^{§§}	54	58	40	74		62		37	66	52	44	25	47
Total number answering question	203	203	167	212		165		139	243	168	151	111	132
Among those who had injected in preceding four weeks													
Level of direct sharing †	24%	25%	19%	21%		21%		19%	16%	22%	22%	16%	23%
Number reporting direct sharing	55	63	36	48		43		23	34	35	30	16	31
Total number answering question	225	252	189	232		207		119	210	158	137	97	137
Level of sharing (direct & indirect) ††	40%	38%	31%	32%		33%		38%	36%	42%	43%	30%	48%
Number reporting sharing	90	95	57	76		69		45	75	67	59	29	67
Total number answering question	226	252	186	234		209		119	211	159	137	97	140
Proportion injecting crack	7.5%	14%	4.5%	5.1%		9.6%		2.5%	6.5%	11%	5.8%	8.2%	9.0%
Number reporting crack injection	17	37	9	12		20		3	14	18	8	8	13
Total number answering question	228	257	198	234		208		120	215	165	139	97	144
Proportion injecting into their groin	32%	28%	31%	27%		25%		33%	34%	41%	38%	39%	45%
Number reporting groin injection	71	71	60	61		51		40	72	68	54	39	65
Total number answering question	221	255	196	226		202		122	213	165	141	99	145
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	15%	11%	15%	10%		23%		6.5%	13%	15%	7.1%	13%	22%
Number always using a condom	15	11	14	12		19		5	17	10	4	5	10
Total number answering question	99	100	93	116		84		77	132	68	56	39	46

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested) x 100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS) x 100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS) x 100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 24: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; Wales: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different. There were changes in the participating areas in Wales during 2013.

<i>Year</i>	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
<i>Sample type</i>	<i>Oral fluid*</i>	<i>Oral fluid*</i>	<i>Oral fluid*</i>	<i>Oral fluid*</i>	<i>Oral fluid*</i>	<i>DBS</i>	<i>DBS</i>	<i>DBS</i>	<i>DBS</i>	<i>DBS</i>	<i>DBS</i>
Anti-HIV Prevalence [†]	0%	0.30%	1.8%	0.57%	0%	1.1%	0%	0.50%	1.1%	0.77%	1.4%
Number of samples anti-HIV positive	0	1	3	1	0	2	0	1	3	2	3
Total number of samples collected	182	330	164	174	196	175	236	201	270	261	217
Anti-HBc Prevalence ^{††}	23%	12%	12%	4.6%	5.4%	11%	10%	13%	11%	11%	13%
Proportion of samples anti-HBc positive	18%	9.1%	9.1%	3.4%	4.1%	11%	10%	13%	11%	11%	13%
Number of samples anti-HBc positive	32	30	15	6	8	20	23	26	30	28	28
Total number of samples collected	182	330	164	174	196	175	236	201	270	261	217
Anti-HCV Prevalence ^{†††}	20%	24%	31%	32%	26%	39%	33%	47%	50%	53%	52%
Proportion of samples anti-HCV positive	19%	22%	29%	29%	24%	39%	33%	47%	50%	53%	52%
Number of samples anti-HCV positive	34	73	47	51	47	68	77	94	136	138	113
Total number of samples collected	182	330	164	174	196	175	236	201	270	261	217
Hepatitis B vaccine uptake	52%	60%	60%	72%	64%	79%	77%	74%	76%	74%	67%
Number reporting hepatitis B vaccine uptake	95	192	98	120	125	136	178	144	195	187	138
Total number answering question	181	321	163	167	194	173	231	195	256	253	206
HCV VCT uptake	60%	61%	74%	75%	62%	86%	84%	84%	85%	81%	82%
Number reporting a VCT for HCV	103	181	116	123	114	138	176	165	223	206	171
Total number answering question	172	299	157	163	185	161	210	196	261	254	208
Proportion aware of HCV infection	59%	30%	51%	45%	34%	56%	42%	38%	48%	47%	56%
Number aware of their HCV infection	17	18	20	19	12	32	26	33	59	53	58
Total number answering question	29	60	39	42	35	57	62	86	123	112	103
HIV VCT uptake	57%	57%	65%	72%	62%	77%	80%	72%	79%	75%	80%
Number reporting a VCT for HIV	100	180	100	121	115	124	175	137	202	189	167
Total number answering question	175	314	154	169	185	162	220	190	256	252	209
Among those who had injected in preceding year											
Symptom^{§§} of injection site infection	30%	30%	32%	20%	24%	30%	27%	29%	35%	39%	34%
Number reporting symptom ^{§§}	28	58	24	19	21	34	43	41	67	77	55
Total number answering question	94	194	75	93	87	112	161	143	193	197	161
Among those who had injected in preceding four weeks											
Level of direct sharing [‡]	23%	17%	28%	17%	20%	11%	10%	21%	22%	13%	11%
Number reporting direct sharing	23	29	19	18	16	12	14	26	34	23	15
Total number answering question	102	173	68	103	81	111	134	125	158	183	142
Level of sharing (direct & indirect) ^{‡‡}	45%	35%	50%	32%	41%	30%	25%	44%	41%	42%	36%
Number reporting sharing	46	62	34	32	33	33	34	56	66	78	51
Total number answering question	102	175	68	100	81	111	134	126	162	186	142
Proportion injecting crack	5.2%	20%	13%	6.8%	8.6%	19%	22%	21%	18%	24%	37%
Number reporting crack injection	5	36	9	7	7	21	29	26	30	43	53
Total number answering question	97	181	71	103	81	108	133	124	165	179	143
Proportion injecting into their groin	13%	25%	26%	8.8%	15%	32%	33%	29%	39%	40%	39%
Number reporting groin injection	13	45	18	9	12	36	44	37	64	75	57
Total number answering question	97	182	70	102	80	111	135	129	165	187	145
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	19%	11%	11%	18%	27%	28%	7.0%	20%	21%	20%	24%
Number always using a condom	10	11	4	8	16	12	3	10	14	14	12
Total number answering question	53	98	37	45	59	43	43	50	67	71	51

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

[†] Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

^{††} Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

^{†††} Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

^{§§} Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

[‡] Sharing of needles and syringes in preceding four weeks.

^{‡‡} Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 25: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use; Northern Ireland: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	1.8%	1.8%	2.6%	1.3%	0%	0.56%	0%	0.62%	0.65%	0.65%	0%
Number of samples anti-HIV positive	3	3	4	2	0	1	0	1	1	1	0
Total number of samples collected	164	165	152	153	193	178	171	161	154	153	126
Anti-HBc Prevalence ††	8.9%	8.1%	7.1%	8.7%	11%	10%	5.8%	6.8%	7.1%	6.5%	6.4%
Proportion of samples anti-HBc positive	6.7%	6.1%	5.3%	6.5%	11%	10%	5.8%	6.8%	7.1%	6.5%	6.4%
Number of samples anti-HBc positive	11	10	8	10	21	18	10	11	11	10	8
Total number of samples collected	164	165	151	153	193	178	171	161	154	153	125
Anti-HCV Prevalence †††	32%	31%	36%	28%	31%	29%	34%	32%	23%	27%	22%
Proportion of samples anti-HCV positive	29%	28%	33%	26%	31%	29%	34%	32%	23%	27%	22%
Number of samples anti-HCV positive	48	47	50	40	60	51	58	51	36	42	28
Total number of samples collected	164	165	152	153	193	178	171	161	154	153	125
Hepatitis B vaccine uptake	80%	77%	82%	80%	73%	68%	68%	75%	78%	84%	82%
Number reporting hepatitis B vaccine uptake	127	125	122	115	138	114	116	116	116	121	101
Total number answering question	159	162	149	144	189	167	170	154	148	144	123
HCV VCT uptake	93%	90%	95%	92%	90%	90%	87%	91%	88%	94%	87%
Number reporting a VCT for HCV	142	138	141	131	170	137	131	137	129	137	107
Total number answering question	153	154	148	143	189	153	150	151	146	145	123
Proportion aware of HCV infection	74%	71%	66%	52%	60%	61%	53%	55%	68%	58%	62%
Number aware of their HCV infection	31	29	29	16	32	25	27	26	23	22	16
Total number answering question	42	41	44	31	53	41	51	47	34	38	26
HIV VCT uptake	80%	80%	84%	92%	89%	89%	86%	90%	91%	92%	88%
Number reporting a VCT for HIV	123	124	124	133	167	143	135	136	134	133	105
Total number answering question	154	155	147	145	188	160	157	151	147	144	120
Among those who had injected in preceding year											
Symptom^{§§} of injection site infection	25%	32%	33%	36%	32%	40%	32%	33%	33%	37%	43%
Number reporting symptom ^{§§}	17	21	26	24	18	29	23	22	19	24	17
Total number answering question	69	65	79	67	56	72	71	67	58	65	40
Among those who had injected in preceding four weeks											
Level of direct sharing †	21%	21%	17%	14%	23%	29%	19%	31%	17%	17%	8.3%
Number reporting direct sharing	9	9	8	6	10	10	6	11	5	6	2
Total number answering question	42	42	47	43	44	35	32	35	30	36	24
Level of sharing (direct & indirect) ††	31%	33%	36%	36%	36%	34%	35%	42%	30%	31%	13%
Number reporting sharing	13	14	17	15	16	12	11	15	9	11	3
Total number answering question	42	42	47	42	44	35	31	36	30	36	24
Proportion injecting crack	2.3%	10%	2.2%	0%	6.8%	0%	3.3%	2.7%	3.6%	0%	0%
Number reporting crack injection	1	4	1	0	3	0	1	1	1	0	0
Total number answering question	43	41	46	40	44	34	30	37	28	36	24
Proportion injecting into their groin	32%	32%	26%	30%	21%	24%	41%	26%	23%	46%	60%
Number reporting groin injection	13	12	12	12	9	8	13	10	7	17	15
Total number answering question	41	38	47	40	42	34	32	38	31	37	25
Among those with two or more (anal or vaginal) sexual partners in preceding year											
Proportion always using a condom	24%	19%	28%	19%	35%	39%	11%	23%	28%	33%	25%
Number always using a condom	13	8	10	6	17	14	4	7	7	8	7
Total number answering question	55	42	36	31	49	36	38	31	25	24	28

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 26: HIV, hepatitis B & hepatitis C prevalence, hepatitis B vaccination uptake, uptake of testing for hepatitis C & HIV, injecting risks, and condom use in those who began injecting in the last three years: 2006-2016

Notes: In 2009 a phased change in the sample type from oral fluid to dried blood spot (DBS) started. The sensitivity of the anti-HCV and anti-HBc tests on these two sample types are different.

Year	2006	2007	2008	2009		2010		2011	2012	2013	2014	2015	2016
Sample type	Oral fluid*	Oral fluid*	Oral fluid*	Oral fluid*	DBS	Oral fluid*	DBS	DBS	DBS	DBS	DBS	DBS	DBS
Anti-HIV Prevalence †	0.77%	1.0%	1.3%	0.71%		0.50%		0.37%	1.0%	1.0%	0.41%	2.6%	1.0%
Number of samples anti-HIV positive	3	5	5	3		2		1	4	3	1	6	2
Total number of samples collected	388	484	391	421		403		269	382	304	243	229	194
Anti-HBc Prevalence ††	14%	6.3%	3.1%	7.1%		7.4%		5.9%	7.1%	5.9%	2.1%	3.5%	3.6%
Proportion of samples anti-HBc positive	10%	4.8%	2.3%	6.1%	2.6%	7.7%	5.7%	5.9%	7.1%	5.9%	2.1%	3.5%	3.6%
Number of samples anti-HBc positive	40	23	9	21	2	12	14	16	27	18	5	8	7
Total number of samples collected	388	484	391	345	76	156	247	269	382	304	243	229	194
Anti-HCV Prevalence †††	23%	23%	24%	24%		23%		20%	24%	24%	19%	24%	27%
Proportion of samples anti-HCV positive	21%	21%	22%	22%	24%	20%	23%	20%	24%	24%	19%	24%	27%
Number of samples anti-HCV positive	81	103	87	77	18	31	57	53	90	74	47	55	53
Total number of samples collected	388	484	391	345	76	156	247	269	382	304	243	229	193
Hepatitis B vaccine uptake	61%	54%	62%	68%		64%		67%	65%	62%	62%	65%	54%
Number reporting hepatitis B vaccine uptake	235	256	238	284		257		178	244	181	144	146	100
Total number answering question	383	477	383	420		400		266	377	294	231	223	186
HCV VCT Uptake	54%	56%	61%	68%		66%		72%	68%	67%	70%	72%	65%
Number reporting a VCT for HCV	198	257	229	272		253		175	236	198	165	160	122
Total number answering question	367	457	373	402		385		243	346	296	236	221	188
Proportion aware of HCV infection	35%	36%	30%	31%		38%		46%	41%	20%	38%	39%	22%
Number aware of their HCV infection	25	35	22	26		28		21	31	13	15	17	10
Total number answering question	71	98	73	84		73		46	76	65	39	44	45
HIV VCT uptake	51%	55%	59%	64%		61%		63%	67%	65%	67%	68%	62%
Number reporting a VCT for HIV	193	257	222	259		235		162	245	192	155	151	117
Total number answering question	377	469	379	405		387		256	364	296	233	222	189
Among those who had injected in preceding year													
Symptom^{§§} of injection site infection	29%	29%	26%	30%		32%		29%	27%	24%	25%	30%	33%
Number reporting symptom ^{§§}	71	89	67	74		66		51	78	53	45	54	46
Total number answering question	244	303	256	250		205		176	286	221	180	182	139
Among those who had injected in preceding four weeks													
Level of direct sharing †	21%	25%	17%	17%		21%		19%	19%	21%	20%	21%	18%
Number reporting direct sharing	57	86	45	46		51		26	46	39	29	27	21
Total number answering question	268	344	258	263		240		139	243	184	145	127	114
Level of sharing (direct & indirect) ††	42%	41%	41%	34%		39%		38%	43%	46%	49%	45%	42%
Number reporting sharing	113	144	103	90		93		53	104	85	72	57	50
Total number answering question	267	347	249	265		241		139	240	185	147	128	118
Proportion injecting crack	28%	26%	26%	23%		22%		29%	30%	31%	28%	40%	50%
Number reporting crack injection	73	88	68	60		52		40	73	56	43	53	57
Total number answering question	265	344	259	261		241		139	241	183	152	131	115
Proportion injecting into their groin	15%	16%	13%	19%		12%		14%	13%	17%	13%	15%	17%
Number reporting groin injection	39	53	33	50		30		19	31	33	20	20	20
Total number answering question	256	337	249	259		248		140	244	190	151	132	118
Among those with two or more (anal or vaginal) sexual partners in preceding year													
Proportion always using a condom	20%	18%	21%	17%		23%		21%	15%	18%	24%	15%	16%
Number always using a condom	23	26	24	23		34		19	17	15	15	9	8
Total number answering question	116	141	116	135		146		91	116	84	63	59	51

* The sensitivity of the oral fluid test for anti-HCV is approximately 92%, and that for anti-HBc is approximately 75%.

† Anti-HIV Prevalence = (number of samples tested anti-HIV positive / total tested)x100.

†† Anti-HBc Prevalence = [(number of oral fluids anti-HBc positive/0.75) + number of DBS anti-HBc positive] / (number of oral fluids + number of DBS)x100.

††† Anti-HCV Prevalence = [(number of oral fluids anti-HCV positive/0.92) + number of DBS anti-HCV positive] / (number of oral fluids + number of DBS)x100.

§§ Self reports of a swelling containing pus (abscess), sore, or open wound at an injection site in preceding year.

† Sharing of needles and syringes in preceding four weeks.

†† Sharing of needles and syringes, mixing containers, or filters among those who had last injected during the four weeks preceding participation in the survey.

Table 27: Characteristics of the people who inject drugs recruited across England, Wales and Northern Ireland: 2006-2016

Notes:

Data on characteristics have not been collected in all years.

Year	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
Under 25 years old ~	14%	15%	13%	13%	11%	8.8%	8.8%	6.0%	5.8%	4.3%	2.6%
Number aged <25 years	455	509	409	400	341	239	287	185	175	116	71
Total number answering question	3,145	3,449	3,066	3,120	3,153	2,731	3,254	3,093	3,037	2,678	2,758
Female gender ~	27%	26%	26%	26%	25%	25%	26%	26%	27%	27%	28%
Number female	870	908	826	851	790	683	851	817	826	718	793
Total number answering question	3,202	3,511	3,170	3,229	3,223	2,785	3,336	3,108	3,067	2,696	2,784
Treatment for drug use*	66%	67%	70%	73%	73%	74%	67%	69%	69%	70%	70%
Number reporting current treatment	2,134	2,355	2,226	2,352	2,360	2,060	2,231	2,137	2,120	1,881	1,940
Total number answering question	3,210	3,522	3,178	3,238	3,230	2,791	3,337	3,119	3,061	2,690	2,775
Ever used a needle exchange	91%	92%	91%	92%	91%	92%	91%	91%	89%	90%	91%
Number reporting use of needle exchange	2,894	3,211	2,880	2,947	2,934	2,530	2,980	2,818	2,709	2,404	2,513
Total number answering question	3,194	3,508	3,159	3,220	3,224	2,760	3,290	3,097	3,034	2,667	2,751
Ever been in prison	66%	68%	68%	72%	70%	71%	72%	71%	69%	67%	68%
Number reporting ever being imprisoned	2,052	2,326	2,106	2,266	2,186	1,922	2,319	2,194	2,084	1,793	1,872
Total number answering question	3,132	3,435	3,089	3,144	3,132	2,704	3,241	3,072	3,022	2,659	2,763
Ever been homeless	74%	76%	74%	77%	76%	77%	78%	76%	74%	74%	75%
Number reporting ever being homeless	2,200	2,574	2,278	2,409	2,381	2,075	2,529	2,332	2,228	1,967	2,072
Total number answering question	2,979	3,405	3,064	3,137	3,132	2,710	3,255	3,075	3,016	2,652	2,756
Ever traded sex for money, goods or drugs						14%	13%	12%	12%	13%	13%
Number reporting ever trading sex**						334	384	345	358	335	361
Total number answering question						2,412	2,997	3,000	2,924	2,586	2,694
<i>Among those who had injected in preceding four weeks</i>											
<i>Stimulant drugs</i>											
Proportion injecting crack	35%	35%	35%	29%	29%	32%	36%	37%	40%	46%	53%
Number reporting crack injection	657	748	640	526	499	421	596	615	627	659	766
Total number answering question	1,887	2,124	1,837	1,808	1,706	1,301	1,672	1,663	1,572	1,428	1,458
Proportion injecting cocaine***	12%	12%	11%	7.7%	6.6%	8.5%	8.7%	6.9%	7.6%	9.7%	10%
Number reporting cocaine injection	218	247	199	140	112	110	145	115	119	139	150
Total number answering question	1,887	2,124	1,837	1,808	1,706	1,301	1,672	1,663	1,572	1,428	1,458
Proportion injecting amphetamine***	16%	19%	18%	17%	18%	23%	22%	23%	24%	17%	17%
Number reporting amphetamine injection	303	394	330	314	308	302	364	382	375	247	244
Total number answering question	1,887	2,124	1,837	1,808	1,706	1,301	1,672	1,663	1,572	1,428	1,458
<i>Higher risk injection sites</i>											
Proportion injecting into their groin	35%	32%	32%	35%	34%	35%	35%	38%	38%	38%	40%
Number reporting groin injection	623	676	579	618	567	459	584	634	598	548	598
Total number answering question	1,800	2,099	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440	1,478
Proportion injecting into their hands***	26%	25%	25%	28%	27%	27%	25%	26%	30%	29%	27%
Number reporting injecting into their hands	461	526	453	491	453	361	430	435	475	418	398
Total number answering question	1,800	2,099	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440	1,478
Proportion injecting into their legs***	19%	19%	18%	19%	18%	21%	20%	21%	23%	26%	26%
Number reporting injecting into their legs	338	401	321	331	311	279	342	356	371	375	386
Total number answering question	1,800	2,099	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440	1,478
Proportion injecting into their feet***	11%	13%	10%	12%	11%	11%	11%	11%	11%	13%	12%
Number reporting injecting into their feet	206	264	189	211	190	149	190	178	181	191	173
Total number answering question	1,800	2,099	1,808	1,781	1,687	1,315	1,690	1,682	1,584	1,440	1,478

~ Age and gender not provided by all participants.

* Prescribed a detox or maintenance drug regime.

** Self-reports of ever receiving money, goods or drugs in exchange for sex.

*** Regional breakdowns not provided due to small numbers.